USRE45666E1 - Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties - Google Patents
Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties Download PDFInfo
- Publication number
- USRE45666E1 USRE45666E1 US13/761,118 US201313761118A USRE45666E US RE45666 E1 USRE45666 E1 US RE45666E1 US 201313761118 A US201313761118 A US 201313761118A US RE45666 E USRE45666 E US RE45666E
- Authority
- US
- United States
- Prior art keywords
- composition
- hydrophilic polymer
- poly
- plasticizing agent
- vinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
- A61L15/585—Mixtures of macromolecular compounds
Definitions
- This invention relates to preparation of adhesive compositions. More particularly, the invention relates to preparation of hydrophilic pressure sensitive adhesive (PSA) compositions having optimized adhesive properties and that are useful, for example, in transdermal drug delivery systems and other medical, pharmaceutical and cosmetic products that adhere to the skin or other body surface.
- PSA pressure sensitive adhesive
- the invention has utility in a number of fields, including transdermal drug delivery, iontophoretic systems, biomedical electrode fabrication, wound healing, and skin care and cosmetic products.
- Pressure-sensitive adhesives are well known and have been used for many years in a variety of industrial, consumer and medical applications. Pressure-sensitive adhesives are characterized as being normally tacky and exhibiting instant tack when applied to a substrate. Many polymers have been used to manufacture pressure sensitive adhesives as, for example, acrylic and methacrylic ester homo- or copolymers, butyl rubber-based systems, silicones, urethanes, vinyl esters and amides, olefin copolymer materials, natural or synthetic rubbers, and the like. All the PSAs are elastomers, i.e. they exhibit viscoelastic properties typical of rubbers.
- Pressure sensitive adhesives are used extensively in transdermal drug delivery devices, or “patches,” that adhere to the skin or mucosal tissue during use.
- Adhesive, transport, reservoir and biological properties of polymeric composites constitute a basis for their application in transdermal drug delivery systems, as follows:
- Examples of pressure sensitive adhesives that have been proposed for use in transdermal drug delivery systems include polysiloxanes (e.g., polydimethyl siloxanes, polydiphenyl siloxanes, and siloxane blends), polyisobutylenes, polyacrylates, acrylic acid-acrylate copolymers (e.g., copolymers of acrylic acid copolymers with 2-ethylhexyl acrylate or isooctyl acrylate), and tacky rubbers such as polyisobutene, polybutadiene, polystyrene-isoprene copolymers, polystyrene-butadiene copolymers, and neoprene (polychloroprene). All of these PSAs are hydrophobic polymers and their common disadvantage is a loss in adhesion toward hydrated substrates.
- PSAs are hydrophobic polymers and their common disadvantage is a loss in adhesion toward hydrated substrates.
- Bioadhesion is defined as a pressure sensitive adhesion with respect to highly hydrated biological tissues such as mucosal tissue.
- PSAs rubber, polysiloxanes and acrylates
- BAs bioadhesives
- water should provide a plasticizing effect on a polymer, i.e., the polymer should be hydrophilic.
- the range of typical BAs includes slightly crosslinked polyacrylic and polymethacrylic acids (EP 0371 421) as well as blends of hydrophilic cellulose derivatives (40-95%) with polyethylene glycol (PEG) (U.S. Pat. No. 4,713,243).
- Bioadhesives become tacky as the crosslinked polymer swells in significant quantities of water.
- the cohesive strength of highly swollen hydrophilic polymers is generally low and the BAs thus differ from the PSAs in this regard.
- PSA and BA polymeric materials of different hydrophilicity and thus different solubilities in water or in the liquids secreted by the skin and mucosa (sweat, mucus, saliva etc.).
- Attempts to combine the properties of PSAs and BAs have been described by Biegajski et al. in U.S. Pat. No. 5,700,478, where a water-soluble pressure-sensitive mucoadhesive was obtained by blending of 95-40% polyvinylpyrrolidone (PVP) with 0-50% hydroxypropyl cellulose (HPC) and 11-60% glycerol.
- PVP polyvinylpyrrolidone
- HPC hydroxypropyl cellulose
- hydrophilic polymer blends coupling the properties of PSAs and BAs involve polyacrylic acid-polyvinyl alcohol (PAA-PVA) interpolymeric complexes formed by hydrogen bonding between the monomer units of the complementary polymers chains and plasticized with PEG-200, glycerol or polypropylene glycol (PPG), molecular weight 425 g/mol (German Patent Application DE 42 19 368).
- PAA-PVA polyacrylic acid-polyvinyl alcohol
- PPG polypropylene glycol
- the ideal performance characteristics of an adhesive intended for use on human skin and/or mucosal tissue present difficult and conflicting technical requirements.
- the pressure sensitive adhesive should be suitable for long-term skin contact, and permeable to and physically and chemically compatible with the active agent and any permeation enhancers or other vehicles or additives that are present.
- the ideal adhesive should also be nonirritating, noncomedogenic and nonsensitizing, yet bond quickly to skin or mucosal tissue at the intended site of use with only very slight pressure.
- the adhesive should maintain its bond for as long a period of time as necessary and be resistant to inadvertent removal, yet be easily removed without removing any skin or leaving a residue (a suitable strength of an adhesive joint with the skin ranges from about 200 to 400 N/m under the 180 degree peel test).
- High tack i.e., greater than about 50 g/cm 2
- the adhesive should not be weakened or destroyed by exposure to moisture or high humidity.
- the adhesive should resist skin movement and be able to transfer a mechanical load from the adhesive backing to the skin.
- the solubility of the active agent in the reservoir of a transdermal drug delivery device is of decisive importance. With higher solubility, it is possible to increase the rate of transdermal delivery (i.e., the rate at which the active agent migrates from the device and into the skin or mucosal tissue). Because many therapeutic agents are ionogenic organic substances having a higher solubility in hydrophilic media than in lipophilic media, adhesive reservoirs based on hydrophilic polymers would be more versatile than adhesive reservoirs based on hydrophobic polymers. Furthermore, as noted above, pressure sensitive adhesives for application to mucosal tissue should adhere well to hydrated substrates, and hydrophilic adhesives would therefore be ideal.
- hydrophobic PSAs have been “hydrophilized” by incorporation of non-tacky hydrophilic polymers and fillers into a hydrophobic adhesive.
- polyisobutylene (PIB) PSA has been hydrophilized by incorporation of cellulose and cellulose derivatives (U.S. Pat. No. 4,231,369), polyvinyl alcohol (PVA), pectin and gelatin (U.S. Pat. Nos. 4,367,732 and 4,867,748), and SiO 2 (U.S. Pat. No. 5,643,187).
- Rubber adhesives have also been modified by filling with amphiphilic surfactants, or by treating the PSA polymer with a plasma-oxygen discharge.
- Acrylic PSAs can be hydrophilized by incorporation of PVP (U.S. Pat. No. 5,645,855). Hydrophilization of hydrophobic adhesives, while somewhat effective, tends to result in a partial loss of adhesion.
- hydrophilic adhesive composition suitable for use in a wide variety of contexts, e.g., in a topically applied drug delivery system, which composition meets all of the above criteria and provides for an effective delivery rate of any active agent, whether hydrophilic, ionogenic, or lipophilic in nature.
- the adhesive compositions combine the properties of pressure-sensitive adhesives and bioadhesives and can be used in a number of contexts, including not only transdermal, transmucosal and topical drug delivery systems but also in wound healing products, biomedical electrodes, iontophoretic systems, bioadhesive cushions, and the like.
- the adhesive compositions can be used with a number of active agents, regardless of hydrophilicity, hydrophobicity, and molecular structure.
- the adhesive composition may be readily tailored during manufacture with respect to hygroscopicity, the desired degree of hydrophilicity, adhesive and cohesive strength, and drug delivery kinetics.
- a method for preparing an adhesive composition having an optimized degree of adhesion comprising:
- T g ⁇ ⁇ predicted w pol T g pol + w pl T g pl ( 1 ) and plotting T g predicted versus w pl , for each composition;
- a method for preparing an adhesive composition having a predetermined degree of adhesion comprising:
- T g ⁇ ⁇ predicted w pol T g pol + w pl T g pl ( 1 ) and plotting T g predicted versus w pl for each composition;
- a hydrophilic pressure sensitive adhesive composition comprises (1) a hydrophilic polymer having a glass transition temperature T g pol , and (2) a complementary hydroxyl-terminated or carboxyl-terminated short-chain plasticizing agent having a glass transition temperature T g pl and capable of hydrogen bonding or electrostatic bonding to the hydrophilic polymer, wherein the weight ratio of hydrophilic polymer to complementary short-chain plasticizing agent is selected so to provide a predetermined deviation in (a) the actual glass transition temperature T g actual of the composition from (b) the predicted glass transition temperature T g predicted calculated for the composition using the Fox equation.
- the predetermined deviation is the maximum negative deviation of T g actual from T g predicted .
- the difference between T g pol and T g pl is at least about 50° C., such that T g actual for each composition is determined solely by T g pl .
- a hydrophilic pressure sensitive adhesive composition comprising (a) a hydrophilic polymer, and (b) a complementary hydroxyl-terminated or carboxyl-terminated short-chain plasticizing agent capable of hydrogen bonding or electrostatic bonding to the hydrophilic polymer, wherein the ratio of hydrogen bonding to covalent crosslinks and/or the ratio of the hydrophilic polymer to the plasticizing agent are selected to optimize the hydrophilicity, adhesive strength and cohesive strength of the composition.
- a drug delivery system for the topical or transdermal administration of a pharmacologically active agent.
- the drug delivery system includes:
- the adhesive compositions herein are also useful in a host of additional applications, e.g., in bandages, wound and burn dressings, ostomy devices, prosthesis securing means, face masks, sound, vibration or impact absorbing materials, and the like.
- the compositions may be rendered electrically conductive by incorporation of water and/or another electrically conductive material, and may thus be used for attaching an electroconductive article, such as an electrode (e.g., a transcutaneous electric nerve stimulation, or “TENS” electrode, an electrosurgical return electrode or an EKG monitoring electrode), to an individual's body surface.
- an electrode e.g., a transcutaneous electric nerve stimulation, or “TENS” electrode, an electrosurgical return electrode or an EKG monitoring electrode
- FIG. 1 represents a schematic view of the molecular design of a hydrogen-bonded or electrostatic-bonded network complex formed by a long-chain hydrophilic polymer and a short-chain plasticizer.
- FIG. 2 is a graph illustrating the adhesion characteristics of a PVP-PEG (m.w. 400 g/mole) blend, evaluated in terms of the 180° peel force needed to rupture an adhesive bond with a polyethylene (PE) substrate at a debonding rate of 10 mm/min, with respect to the compositional behavior of the glass transition temperature, T g , in the blend.
- the points denote experimental data, whereas the line connecting the T g s of PVP and PEG-400 was obtained using the Fox equation.
- FIG. 3 is a plot of ⁇ C p T g against the composition of PVP blends with PEG-400.
- FIG. 4 shows the effects of the plasticizer-hydrophilic polymer ratio and the relative humidity of the surrounding atmosphere on the adhesion of PVP plasticized with PEG-400, evaluated in terms of 180° peel force.
- FIG. 5 represents the Kovacs plot for miscible PVP-PEG blends.
- FIG. 6 illustrates the squeezing kinetics of PVP-PEG adhesive hydrogel under a fixed compressive load and squeeze recoil upon its removal.
- the h value is the distance (mm) between the upper and lower plates of the squeeze-recoil tester, which is equal to the thickness of specimen.
- FIG. 7 is the PVP-PEG adhesive hydrogel flow curve under a compressive load of 1 N at 20° C.
- FIG. 8 outlines the creep-recoil functions for the PVP-PEG adhesive hydrogel compared to polybutadiene (PB) and polyisoprene (PI) rubbers.
- FIG. 9 exhibits the water vapor absorption isotherms for PVP and its blends with PEG-400 at ambient temperature.
- FIG. 10 displays the isotherms of water vapor sorption by polyvinyl caprolactam (PVCap) and PVP at ambient temperature.
- FIG. 11 outlines the effect of relative humidity (RH) on the adhesion of PVP-PEG and PVCap-PEG hydrogels.
- active agent drug
- therapeutic agent a chemical material or compound suitable for transdermal or transmucosal administration and which induces a desired effect.
- agents that are therapeutically effective, prophylactically effective, or cosmetically effective are also included.
- derivatives and analogs of those compounds or classes of compounds specifically mentioned which also induce the desired effect.
- transdermal drug delivery is meant administration of a drug to the skin surface of an individual so that the drug passes through the skin tissue and into the individual's blood stream.
- transdermal is intended to include “transmucosal” drug administration, i.e., administration of a drug to the mucosal (e.g., sublingual, buccal, vaginal, rectal) surface of an individual so that the drug passes through the mucosal tissue and into the individual's blood stream.
- Topical administration is used in its conventional sense to mean delivery of an active agent to the skin or mucosa, as in, for example, topical drug administration in the prevention or treatment of various skin disorders, the application of cosmetics and cosmeceuticals (including moisturizers, masks, sunscreens, etc.), and the like.
- Topical administration in contrast to transdermal administration, provides a local rather than a systemic effect.
- body surface is used to refer to skin or mucosal tissue, including the interior surface of body cavities that have a mucosal lining.
- skin should be interpreted as including “mucosal tissue” and vice versa.
- transdermal when used herein, as in “transdermal drug administration” and “transdermal drug delivery systems,” it is to be understood that unless explicitly indicated to the contrary, both “transmucosal” and “topical” administration and systems are intended as well.
- Hydrophilic polymers and “hydrophilic” polymers are defined herein as suggested by Zaikov et al. (1987), “Diffusion of electrolytes in polymers,” VSP (Utrecht—Tokyo). It is based on the amount of water vapor absorbed by polymers at 100% relative humidity. According to this classification, the hydrophobic polymers absorb only up to 1 wt. % water at 100% relative humidity (“rh”), while the moderately hydrophilic polymer absorbs 1-10% wt. % of water at 100% rh. Hydrophilic polymers are capable of sorbing more than 10 wt. % of water, while hygroscopic polymers sorb more than 20 wt. % of water.
- crosslinked refers to a composition containing intramolecular and/or intermolecular crosslinks, whether arising through covalent or noncovalent bonding.
- Noncovalent bonding includes hydrogen bonding, electrostatic (ionic) bonding, and absorption.
- tack and “tacky” are qualitative. However, the terms “substantially nontacky” “slightly tacky” and “tacky,” as used herein, may be quantified using the values obtained in a PKI or TRBT tack determination method, as follows.
- substantially nontacky is meant a composition that has a tack value that is less than about 25 g-cm/sec
- lightly tacky is meant a composition that has a tack value in the range of about 25 g-cm/sec to about 100 g-cm/sec
- tack is meant a hydrogel that has a tack value of at least 100 g-cm/sec.
- the invention provides a method for obtaining hydrophilic PSAs by mixing a specific amount of a selected hydrophilic polymer with a specific amount of a selected complementary short-chain plasticizer capable of hydrogen bonding to the hydrophilic polymer.
- Suitable hydrophilic polymers include repeating units derived from an N-vinyl lactam monomer, a carboxy vinyl monomer, a vinyl ester monomer, an ester of a carboxy vinyl monomer, a vinyl amide monomer, and/or a hydroxy vinyl monomer.
- Such polymers include, by way of example, poly(N-vinyl lactams), poly(N-vinyl acrylamides), poly(N-alkylacrylamides), substituted and unsubstituted acrylic and methacrylic acid polymers, polyvinyl alcohol (PVA), polyvinylamine, copolymers thereof and copolymers with other types of hydrophilic monomers (e.g. vinyl acetate).
- Poly(N-vinyl lactams) useful herein are preferably non-crosslinked homopolymers or copolymers of N-vinyl lactam monomer units, with N-vinyl lactam monomer units representing the majority of the total monomeric units of a poly(N-vinyl lactams) copolymer.
- Preferred poly(N-vinyl lactams) for use in conjunction with the invention are prepared by polymerization of one or more of the following N-vinyl lactam monomers: N-vinyl-2-pyrrolidone; N-vinyl-2-valerolactam; and N-vinyl-2-caprolactam.
- Nonlimiting examples of non-N-vinyl lactam comonomers useful with N-vinyl lactam monomeric units include N,N-dimethylacrylamide, acrylic acid, methacrylic acid, hydroxyethylmethacrylate, acrylamide, 2-acrylamido-2-methyl-1-propane sulfonic acid or its salt, and vinyl acetate.
- Poly (N-alkylacrylamides) include, by way of example, poly(methacrylamide) and poly(N-isopropyl acrylamide) (PNIPAM).
- Polymers of carboxy vinyl monomers are typically formed from acrylic acid, methacrylic acid, crotonic acid, isocrotonic acid, itaconic acid and anhydride, a 1,2-dicarboxylic acid such as maleic acid or fumaric acid, maleic anhydride, or mixtures thereof, with preferred hydrophilic polymers within this class including polyacrylic acid and polymethacrylic acid, with polyacrylic acid most preferred.
- Preferred hydrophilic polymers herein are the following: poly(N-vinyl lactams), particularly polyvinyl pyrrolidone (PVP) and poly(N-vinyl caprolactam) (PVC); poly(N-vinyl acetamides), particularly polyacetamide per se; polymers of carboxy vinyl monomers, particularly polyacrylic acid and polymethacrylic acid; and copolymers and blends thereof. PVP and PVC are particularly preferred.
- the molecular weight of the hydrophilic polymer is not critical; however, the weight average molecular weight of the hydrophilic polymer is generally in the range of approximately 100,000 to 2,000,000, more typically in the range of approximately 500,000 to 1,500,000.
- the hydrophilic polymer may or may not be adhesive in nature, as a nonadhesive hydrophilic polymer will become adhesive upon admixture with a predetermined quantity of the plasticizing agent.
- the complementary short-chain plasticizing agent is terminated with hydroxyl groups, amino or carboxyl groups, and is typically a monomeric or oligomeric material that has a glass transition temperature T g in the range of about ⁇ 100° C. to about ⁇ 30° C. and a melting temperature T m lower than about 20° C.
- the plasticizing agent may be also amorphous.
- the difference between the T g values of polymer and plasticizer has a decisive significance for the adhesive behavior of the polymer-plasticizer blend. Preferably, the difference is greater than about 50° C., preferably greater than about 100° C., and most preferably in the range of about 150° C. to about 300° C.
- the hydrophilic polymer and complementary short-chain plasticizer should be compatible, i.e.
- the plasticizing agent will have a molecular weight in the range from about 45 to about 800, preferably in the range of about 45 to about 600.
- suitable plasticizing agents include, but are not limited to, low molecular weight polyalcohols (e.g.
- glycerol monomeric or oligoalkylene glycols such as ethylene glycol and propylene glycol, ether alcohols (e.g., glycol ethers), alkane diols from butane diol to octane diol includingly, carboxyl-terminated and amino-terminated derivatives of polyalkylene glycols such as polyethylene glycol, and carbonic diacids.
- ether alcohols e.g., glycol ethers
- alkane diols from butane diol to octane diol includingly, carboxyl-terminated and amino-terminated derivatives of polyalkylene glycols such as polyethylene glycol, and carbonic diacids.
- Polyalkylene glycols, optionally carboxyl-terminated, are preferred herein, and polyethylene glycol having a molecular weight in the range of about 300 to 600 is an optimal plasticizing agent.
- the hydrophilic polymer and plasticizer should be miscible with respect to each other and have disparate chain lengths (as may be deduced from the above).
- the ratio of the weight average molecular weight of the hydrophilic polymer to that of the short-chain plasticizer should be within about 200 and 200,000, preferably within about 1,250 and 20,000.
- the polymer and the plasticizer should contain complementary functional groups capable of hydrogen bonding or electrostatic bonding to each other.
- the complementary functional groups of the polymer are located throughout the polymeric structure, while the functional groups of the plasticizer are preferably located at the two termini of a linear molecule, and are not present along the backbone, if the plasticizer is a polymer or an oligomer.
- the plasticizer has been found to decrease the glass transition temperature of the hydrophilic polymer/plasticizer composition to a greater degree than predicted by the Fox equation, which is given by equation (1)
- T g ⁇ ⁇ predicted w pol T g pol + w pl T g pl ( 1 )
- T g predicted is the predicted glass transition temperature of the hydrophilic polymer/plasticizer composition
- w pol is the weight fraction of the hydrophilic polymer in the composition
- w pl is the weight fraction of the plasticizer in the composition
- T g pol is the glass transition temperature of the hydrophilic polymer
- T g pl is the glass transition temperature of the plasticizer.
- an adhesive composition having an optimized (e.g., maximized) degree of adhesion can be prepared from a hydrophilic polymer and a complementary plasticizer by selecting the components and their relative amounts to give a predetermined deviation from T g predicted , even if each component individually is non-tacky.
- the predetermined deviation from T g predicted will be the maximum negative deviation, such that this is the point where adhesive strength is maximized.
- the weight ratio of hydrophilic polymer to plasticizer should be of a specified value in order for adhesion to appear in a blend of a non-tacky hydrophilic polymer and a short-chain complementary plasticizer.
- FIG. 2 illustrates, in PVP blends with PEG-400 adhesion is inherent only in those compositions that demonstrate negative deviations from the T g value predicted by the Fox equation (1). The larger the negative deviation, the higher the adhesion. This finding is generally applicable and is not limited to PVP-PEG-400 blends.
- the negative deviation is within the range about 30° C. to about 150° C., preferentially from about 50° C. to about 120° C.
- the extent of the negative T g deviation depends on the difference between the T g s of blend components, i.e., between T g pol and T g pl . In general, the negative T g deviation should be approximately 20-40% of the difference between the T g values of unblended polymer and plasticizer.
- ⁇ C p T g product Another general predictor of pressure-sensitive adhesive behavior in polymers is the ⁇ C p T g product, where ⁇ C p is the change in heat capacity at the polymer transition point from the glassy to the viscoelastic state.
- This product features a measure of the amount of heat that has to be expended in order to provide the polymer transition from the glassy to the viscoelastic state and to impart translational mobility to polymeric segments.
- the ⁇ C p T g product decreases, passing through a minimum that corresponds to the maximum in blend adhesion ( FIG. 3 ). It is the product ⁇ C p T g which sets the PSAs apart from non-adhesive polymers (Table 1).
- ⁇ C p T g values which are associated with the adhesive PVP-PEG blends and hydrophobic PSA's (PDMS, PIB and natural rubber), are notably grouped within a narrow area ranging from 45.0 to 92.0 J/g, predominantly near 65-80 J/g.
- Non-adhesive polymers exhibit higher ⁇ C p T g values.
- the ⁇ C p T g value outlines a subtle balance between free volume and cohesive interactions energy in polymers (Feldstein et al. (1999), Polym Mater. Sci. Eng. 81:467-468).
- the enhanced free volume has to be counterbalanced by a high attractive interaction energy in order for adhesion to appear.
- Enhanced free volume results in high molecular mobility and liquid-like fluidity of a PSA polymer, whereas substantial cohesive interaction energy provides cohesive toughness and rubber-like resistance to flow.
- T g actual for the present adhesive compositions will generally be substantially lower than that predicted by the Fox equation, particularly since the composition of preferred adhesives herein is selected to correspond to the maximum negative deviation of T g actual from T g predicted , the heat required to transform a glassy polymer blend to a viscoelastic composition is minimal.
- Equation (2) establishes a general relation of adhesive strength to the measures of molecular mobility (D) and cohesive toughness ( ⁇ f ) of PSA polymer.
- equation (2) explains why adhesion goes through a maximum upon mixing a hydrophilic polymer with a short-chain plasticizer bearing complementary reactive functional groups at the chain ends.
- Forming hydrogen or electrostatic bonds through both terminal groups of the plasticizer provides noncovalent crosslinking of the hydrophilic polymer chains into a supramolecular network structure of a polymer blend. Due to the considerable length and flexibility of plasticizer chains, the network structure provides enhanced free volume and molecular mobility coupled with high cohesive strength, i.e. the properties governing the adhesive behavior of polymer blends. With the increase in plasticizer concentration the molecular mobility (D) increases, whereas the cohesive strength ( ⁇ f ) follows the opposite pattern.
- the PVP-PEG system is considered here as a model, but it is to be understood that the invention is not limited in this regard, and a number of hydrophilic polymers and plasticizers may be substituted for PVP and PEG, respectively.
- the broad applicability of the invention results primarily from the properties of the plasticizers rather than those of the hydrophilic polymers. This fundamental conclusion has also a theoretical confirmation. As is evident from Examples 1-67, a specific type of compositional behavior of the blend T g , outlined by both the negative deviations from the weight-average magnitudes obtained with the Fox equation (1), ⁇ T g , and the ⁇ C p T g quantity, is a factor controlling adhesion.
- the Kovacs equation (3) holds if the difference in T g between the glass transition temperature of a PEG plasticizer component and the glass transition temperature of a PVP polymer (and between any miscible hydrophilic polymer and complementary plasticizer) is larger than about 50° C.:
- T g T gPEG + f gPVP ⁇ PEG ⁇ ⁇ PVP ⁇ PEG ( 3 )
- f g the fractional free volume of PVP at T g
- ⁇ the thermal expansion coefficient for PEG
- ⁇ polymer volume fraction in the blend.
- the f g factor has been found to be of the same universal magnitude, about 0.025, for all polymers (see Ferry (1970). Viscoelastic Properties of Polymers, 2nd Ed., Wiley: N.Y., Chapter 11).
- the Kovacs equation (3) manifests theoretically that the specific behavior of a PVP-PEG system is due to the PEG properties.
- Equation (3) indicates also that for every given short-chain telechelic plasticizer, the blend composition that corresponds to the maximum negative deviation in T g actual from T g predicted and, consequently, to the maximum adhesion, is practically unaffected by the structure of the higher-T g hydrophilic complementary polymer.
- the highest degree of adhesive strength appears in PVP-PEG blends at a PEG concentration of 36 wt. %
- PEG blends with other complementary hydrophilic polymers will also exhibit the maximum degree of adhesion in vicinity of 36 wt. % plasticizer, providing that the T g of the hydrophilic polymer is more than 50° C. higher than the T g of the plasticizer.
- hydrophilic polymer and the plasticizing agent are blended in a ratio designed to optimize adhesive and cohesive strength as well as hydrophilicity and thus, in drug delivery systems, the kinetics of drug delivery.
- the ratio is as discussed above, i.e., a preferred weight ratio of hydrophilic polymer to plasticizer should be in the range defined by the maximum values of the negative T g deviations from the weight-average magnitudes calculated using the Fox equation (1) or outlined by the minimum values of the ⁇ C p T g criterion ( FIGS. 2 and 3 ).
- the free volume and cohesive energy of polymer compositions have to be in a specified ratio in order for a composition to exhibit pressure-sensitive adhesion.
- Feldstein et al. (1999) “Quantitative relationship between molecular structure and adhesion of PVP-PEG hydrogels,” Polym. Mater. Sci. Eng. 81:465-466; Feldstein et al. (1999), “Contribution of molecular mobility to debonding of pressure sensitive adhesive hydrogels,” Polym. Mater. Sci. Eng. 81:465-466; Feldstein et al. (1999), “A structure—property relationship and quantitative approach to the development of universal transdermal drug delivery system,” in: T. Sohn and V. A.
- the composition may or may not be hydrated, depending on the desired use.
- transdermal and transmucosal drug delivery systems will generally contain zero to about 7 wt. % water
- products such as facial masks, electroconductive adhesive products, cosmeceutical products, topical pharmaceutical formulations, and other products in which a gel type adhesive (i.e., a hydrogel adhesive) is desired, will generally contain about 7 wt. % to about 40 wt. % water.
- the optimum degree of hydration depends on the nature and hygroscopic of the hydrophilic polymer and the short-chain plasticizer. For example, an optimum PVP-PEG-400 system for most uses will contain from 2 to 20 wt.
- % of residual water preferably from 2 to 12 wt. % water, most preferably between 6 and 10 wt. % water.
- the rise in plasticizer hygrosopicity with the decrease in PEG chain length leads to an increase in the degree of optimum hydration, whereas the replacement of highly hygrosopic PVP with less hygrosopic PVCap results in the decrease of hydration providing best adhesion.
- some hydration will occur upon application of the adhesive composition to skin or other body surface.
- a hydrogel may be advantageous in a number of contexts.
- compositions are self-adhesive and normally do not require the addition of tackifiers.
- other additives may be incorporated into the present adhesive compositions, so long as they are not detrimental to the composition in any way.
- the following optional components are often present in adhesive formulations and are presented here for illustrative purposes only and are not meant to limit the adhesive compositions in any way.
- These optional components include including fillers, chain transfer agents for controlling molecular weight (e.g., carbon tetrabromide, mercaptans, or alcohols), pigments, dyes, refractive particles, preservatives, stabilizers, toughening agents, antimicrobial agents (e.g., mercurochrome, silver sulfadiazine, povidine iodine, iodine), cosmetic agents (e.g., glycerine, urea, allantoin, sulfur, anthraquinone, hydroquinones), moisturizers, humectants, anesthetics (e.g., benzocaine), healing agents (e.g., collagen), and the like.
- chain transfer agents for controlling molecular weight e.g., carbon tetrabromide, mercaptans, or alcohols
- pigments e.g., carbon tetrabromide, mercaptans, or alcohols
- dyes e
- Insoluble fibrous fillers may be advantageously incorporated to control the degree of hydration when the adhesive is on the skin or other body surface.
- Such fillers can include cellulosic materials as described in International Patent Publication No. WO 89/03859, e.g., woven and non-woven paper and cotton materials.
- Other suitable fillers are inert, i.e., substantially non-adsorbent, and include, for example, polyethylenes, polypropylenes, polyurethane polyether amid copolymers, polyesters and polyester copolymers, nylon and rayon. These additives, and amounts thereof, are selected in such a way that they do not significantly interfere with polymerization, crosslinking or the desired chemical and physical properties of the final adhesive.
- the adhesive compositions may be rendered electrically conductive for use in biomedical electrodes and other electrotherapy contexts, i.e., to attach an electrode or other electrically conductive member to the body surface.
- the adhesive compositions may be used to attach a transcutaneous nerve stimulation electrode, an electrosurgical return electrode, or an EKG electrode to a patient's skin or mucosal tissue.
- these applications involve modification of the adhesive composition so as to contain a conductive species, thereby rendering the adhesive composition as a whole conductive.
- Suitable conductive species include the ionically conductive electrolytes that are commonly used for application to the skin or other body surface, and include ionizable inorganic salts, organic compounds, or combinations of both.
- ionically conductive electrolytes include, but are not limited to, ammonium sulfate, ammonium acetate, monoethanolamine acetate, diethanolamine acetate, sodium lactate, sodium citrate, magnesium acetate, magnesium sulfate, sodium acetate, calcium chloride, magnesium chloride, calcium sulfate, lithium chloride, lithium perchlorate, sodium citrate and potassium chloride, and redox couples such as a mixture of ferric and ferrous salts such as sulfates and gluconates.
- Preferred salts are potassium chloride, sodium chloride, magnesium sulfate, and magnesium acetate, and potassium chloride is most preferred for EKG applications.
- any amount of electrolyte may be present in the adhesive compositions of the invention, it is preferable that any water-soluble electrolyte be present at a concentration in the range of about 0.1 to about 15 wt % of the mixture.
- the procedure described in U.S. Pat. No. 5,846,558 to Nielsen et al. for fabricating biomedical electrodes may be adapted for use with the adhesive compositions of the invention, and the disclosure of that patent is incorporated by reference with respect to manufacturing details. Other suitable fabrication procedures may be used as well, as will be appreciated by those skilled in the art.
- the adhesive composition should be covalently crosslinked.
- the hydrophilic polymer may be covalently crosslinked, either intramolecularly or intermolecularly, and/or the hydrophilic polymer and the plasticizer may be covalently crosslinked. In the former case, there are no covalent bonds linking the hydrophilic polymer to the plasticizer, while in the latter case, there are covalent crosslinks binding the hydrophilic polymer to the plasticizer.
- the hydrophilic polymer, or the hydrophilic polymer and the plasticizer may be covalently crosslinked using heat, radiation, or a chemical curing (crosslinking) agent.
- a free radical polymerization initiator should be added into the polymer blend, i.e., the admixture of the hydrophilic polymer and the plasticizer.
- the free radical polymerization initiator can be any of the known free radical-generating initiators conventionally used in vinyl polymerization and is preferably an organic peroxide or azo compound.
- the initiators can be used in conventional amounts, generally from 0.01 to 15%, preferably 0.05 to 10%, more preferably from about 0.1% to about 5% and especially from a out 0.5% to about 4% by weight of the polymerisable material.
- Suitable organic peroxides include dialkyl peroxides such as t-butyl peroxide and 2,2 bis(t-butylperoxy)propane, diacyl peroxides such as benzoyl peroxide and acetyl peroxide, peresters such as t-butyl perbenzoate and t-butyl per-2-ethylhexanoate, perdicarbonates such as dicetyl peroxy dicarbonate and dicyclohexyl peroxy dicarbonate, ketone peroxides such as cyclohexanone peroxide and methylethylketone peroxide, and hydroperoxides such as cumene hydroperoxide and tert.butyl hydroperoxide.
- dialkyl peroxides such as t-butyl peroxide and 2,2 bis(t-butylperoxy)propane
- diacyl peroxides such as benzoyl peroxide and acetyl
- Suitable azo compounds include azo bis (isobutyronitrile) and azo bis (2,4-dimethylvaleronitrile).
- the temperature and thermally crosslink the adhesive composition will depend on the actual components and may be readily deduced by one of ordinary skill in the art, but typically ranges from about 80° C. to about 200° C.
- the hydrophilic polymer, or the hydrophilic polymer and the plasticizer may also be crosslinked with radiation, typically in the presence of a photoinitator.
- the radiation may be ultraviolet, alpha, beta, gamma, electron beam, and x-ray radiation, although ultraviolet radiation is preferred.
- Useful photosensitizers are triplet sensitizers of the “hydrogen abstraction” type, and include benzophenone and substituted benzophenone and acetophenones such as benzyl dimethyl ketal, 4-acryloxybenzophenone (ABP), 1-hydroxy-cyclohexyl phenyl ketone, 2,2-diethoxyacetophenone and 2,2-dimethoxy-2-phenylacetophenone, substituted alpha-ketols such as 2-methyl-2-hydroxypropiophenone, benzoin ethers such as benzoin methyl ether and benzoin isopropyl ether, substituted benzoin ethers such as anisoin methyl ether, aromatic sulfonyl chlorides such as 2-naphthalene sulfonyl chloride, photoactive oximes such as 1-phenyl-1,2-propanedione-2-(O-ethoxy-carbonyl)-oxime, thioxanthones including alkyl
- photosensitizers of the hydrogen abstraction type higher intensity UV exposure may be necessary to achieve sufficient crosslinking.
- Such exposure can be provided by a mercury lamp processor such as those available from PPG, Fusion, Xenon, and others.
- Crosslinking may also be induced by irradiating with gamma radiation or an electron beam. Appropriate irradiation parameters, i.e., the type and dose of radiation used to effect crosslinking, will be apparent to those skilled in the art.
- Suitable chemical curing agents also referred to as chemical cross-linking “promoters,” include, without limitation, polymercaptans such as 2,2-dimercapto diethylether, dipentaerythritol hexa(3-mercaptopropionate), ethylene bis(3-mercaptoacetate), pentaerythritol tetra(3-mercaptopropionate), pentaerythritol tetrathioglycolate, polyethylene glycol dimercaptoacetate, polyethylene glycol di(3-mercaptopropionate), trimethylolethane tri(3-mercaptopropionate), trimethylolethane trithioglycolate, trimethylolpropane tri(3-mercaptopropionate), trimethylolpropane trithioglycolate, dithioethane, di- or trithiopropane and 1,6-hexane dithiol.
- the crosslinking promoter is added to
- the hydrophilic polymer may also be crosslinked prior to admixture with the plasticizer. In such a case, it may be preferred to synthesize the polymer in crosslinked form, by admixing a monomeric precursor to the polymer with multifunctional comonomer and copolymerizing.
- Examples of monomeric precursors and corresponding polymeric products are as follows: N-vinyl amide precursors for a poly(N-vinyl amide) product; N-alkylacrylamides for a poly(N-alkylacrylamide) product; acrylic acid for a polyacrylic acid product; methacrylic acid for a polymethacrylic acid product; acrylonitrile for a poly(acrylonitrile) product; and N-vinyl pyrrolidone (NVP) for a polyviny lpyrrolidone product.
- Polymerization may be carried out in bulk, in suspension, in solution, or in an emulsion.
- Solution polymerization is preferred, and polar organic solvents such as ethyl acetate and lower alkanols (e.g., ethanol, isopropyl alcohol, etc.) are particularly preferred.
- polar organic solvents such as ethyl acetate and lower alkanols (e.g., ethanol, isopropyl alcohol, etc.) are particularly preferred.
- synthesis will typically take place via a free radical polymerization process in the presence of a free radical initiator as described above.
- the multifunctional comonomer include, for example, bisacrylamide, acrylic or methacrylic esters of diols such as butanediol and hexanediol (1,6-hexane diol diacrylate is preferred), other acrylates such as pentaerythritol tetraacrylate, and 1,2-ethylene glycol diacrylate, and 1,12-dodecanediol diacrylate.
- multifunctional crosslinking monomers include oligomeric and polymeric multifunctional (meth)acrylates, e.g., poly(ethylene oxide) diacrylate or poly(ethylene oxide) dimethacrylate; polyvinylic crosslinking agents such as substituted and unsubstituted divinylbenzene; and difunctional urethane acrylates such as EBECRYL® 270 and EBECRYL® 230 (1500 weight average molecular weight and 5000 weight average molecular weight acrylated urethanes, respectively—both available from UCB of Smyrna, Ga.), and combinations thereof.
- oligomeric and polymeric multifunctional (meth)acrylates e.g., poly(ethylene oxide) diacrylate or poly(ethylene oxide) dimethacrylate
- polyvinylic crosslinking agents such as substituted and unsubstituted divinylbenzene
- difunctional urethane acrylates such as EBECRYL® 270 and EBECRYL® 230 (1500
- the amount used will preferably be such that the weight ratio of crosslinking agent to hydrophilic polymer is in the range of about 1:100 to 1:5.
- chemical crosslinking is combined with radiation curing.
- the adhesive compositions of the invention are extrudable, and thus may be prepared using a simple blending and extruding process.
- the components of the composition are weighed out and then admixed, for example using a Baker Perkins Blender, generally although not necessarily at an elevated temperature, e.g., about 35° C. to about 90° C.
- Solvents may, if desired, be added.
- Preferred solvents are aqueous solvents or alcohols (e.g., ethanol, methanol, isopropanol, etc.). Any crosslinking is carried out subsequently.
- the resulting composition can be extruded using a single or twin extruder, or pelletized.
- the adhesive composition may be prepared or extruded onto the backing layer or release liner of such a system.
- drug delivery systems generally comprise: (A) a drug reservoir containing a therapeutically effective amount of the active agent; (B) an adhesive means for maintaining the system in active agent transmitting relationship to a body surface; and (C) a backing layer that serves as the outer surface of the device during use, wherein (D) a release liner generally covers the exposed adhesive during storage and prior to use.
- Suitable active agents include the broad classes of compounds normally delivered through body surfaces and membranes; these active agents, in general, include: analeptic agents; analgesic agents; anesthetic agents; antiarthritic agents; respiratory drugs, including antiasthmatic agents; anticancer agents, including antineoplastic drugs; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics and antiviral agents; antiinflammatory agents; antimigraine preparations; antinauseants; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents; antiviral agents; anxiolytics; appetite suppressants; attention deficit disorder (“ADD”) and attention deficit hyperactivity disorder (“ADD”) and attention deficit hyperactivity disorder (“ADD”) and attention deficit hyperactivity
- Specific active agents with which the present adhesive compositions are useful include, without limitation, anabasine, capsaicin, isosorbide dinitrate, aminostigmine, glyceryl trinitrate, verapamil, propranolol, silabolin, foridone, clonidine, cytisine, phenazepam, nifedipine, fluacizin, and salbutamol.
- Suitable enhancers include, for example, the following: sulfoxides such as dimethylsulfoxide (DMSO) and decylmethylsulfoxide (C 10 MSO); ethers such as diethylene glycol monoethyl ether (available commercially as Transcutol®) and diethylene glycol monomethyl ether; surfactants such as sodium laurate, sodium lauryl sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, Poloxamer (231, 182, 184), Tween (20, 40, 60, 80) and lecithin (U.S.
- sulfoxides such as dimethylsulfoxide (DMSO) and decylmethylsulfoxide (C 10 MSO)
- ethers such as diethylene glycol monoethyl ether (available commercially as Transcutol®) and diethylene glycol monomethyl ether
- surfactants such as sodium laurate, sodium lauryl sulfate, cetyl
- alcohols such as ethanol, propanol, octanol, decanol, benzyl alcohol, and the like
- fatty acids such as lauric acid, oleic acid and valeric acid
- fatty acid esters such as isopropyl myristate, isopropyl palmitate, methylpropionate, and ethyl oleate
- polyols and esters thereof such as propylene glycol, ethylene glycol, glycerol, butanediol, polyethylene glycol, and polyethylene glycol monolaurate (“PEGML”; see, e.g., U.S. Pat.
- amides and other nitrogenous compounds such as urea, dimethylacetamide (DMA), dimethylformamide (DMF), 2-pyrrolidone, 1-methyl-2-pyrrolidone, ethanolamine, diethanolamine and triethanolamine; terpenes; alkanones; and organic acids, particularly salicylic acid and salicylates, citric acid and succinic acid.
- DMA dimethylacetamide
- DMF dimethylformamide
- 2-pyrrolidone 2-pyrrolidone
- 1-methyl-2-pyrrolidone 1-methyl-2-pyrrolidone
- ethanolamine diethanolamine and triethanolamine
- terpenes alkanones
- organic acids particularly salicylic acid and salicylates, citric acid and succinic acid.
- a preferred enhancer is ethanol, which not only serves as a permeation enhancer, but also solubilizes many active agents of interest and in addition improves adhesion.
- An ethanol-water mixture may also be used.
- a range of above mentioned skin permeability enhancers serves concomitantly in the adhesive composition as appropriate plasticizing agents, e.g. polyols such as propylene glycol, ethylene glycol, glycerol, butanediol, hexanediol and polyethylene glycol.
- plasticizing agents e.g. polyols such as propylene glycol, ethylene glycol, glycerol, butanediol, hexanediol and polyethylene glycol.
- the backing layer of the transdermal drug delivery device functions as the primary structural element of the transdermal system and provides the device with flexibility, drape and, optionally, occlusivity.
- the material used for the backing layer should be inert and incapable of absorbing drug, enhancer or other components of the pharmaceutical composition contained within the device.
- the material used for the backing layer should permit the device to follow the contours of the skin and be worn comfortably on areas of skin such as at joints or other points of flexure, that are normally subjected to mechanical strain with little or no likelihood of the device disengaging from the skin due to differences in the flexibility or resiliency of the skin and the device.
- Examples of materials useful for the backing layer are polyesters, polyethylene, polypropylene, polyurethanes and polyether amides.
- the layer is preferably in the range of about 15 microns to about 250 microns in thickness, and may, if desired, be pigmented, metallized, or provided with a matte finish suitable for writing.
- the layer is preferably nonocclusive (or “breathable”), i.e., is preferably permeable to moisture.
- the laminated structure includes a release liner. Immediately prior to use, this layer is removed from the device so that the system may be affixed to the skin.
- the release liner should be made from a drug/vehicle impermeable material, and is a disposable element which serves only to protect the device prior to application.
- the release liner is formed from a material impermeable to the components of the device and the pharmaceutical composition contained therein.
- Additional layers may also be present in any of these drug delivery systems.
- Fabric layers may be used to facilitate fabrication of the device, while a rate-controlling membrane may be used to control the rate at which a component permeates out of the device.
- the component may be a drug, a permeation enhancer, or some other component contained in the drug delivery system.
- a rate-controlling membrane in the system on the skin side of the drug reservoir.
- the materials used to form such a membrane are selected to limit the flux of one or more components contained in the drug formulation, and the membrane may be either microporous or dense.
- Representative materials useful for forming rate-controlling membranes include polyolefins such as polyethylene and polypropylene, polyamides, polyesters, ethylene-ethacrylate copolymer, ethylene-vinyl acetate copolymer, ethylene-vinyl methylacetate copolymer, ethylene-vinyl ethylacetate copolymer, ethylene-vinyl propylacetate copolymer, polyisoprene, polyacrylonitrile, ethylene-propylene copolymer, polysiloxane-polycarbonate block copolymer and the like.
- polyolefins such as polyethylene and polypropylene, polyamides, polyesters, ethylene-ethacrylate copolymer, ethylene-vinyl acetate copolymer, ethylene-vinyl methylacetate copolymer, ethylene-vinyl ethylacetate copolymer, ethylene-vinyl propylacetate copolymer, polyiso
- the adhesive compositions of the invention are useful in any number of additional contexts wherein adhesion of a product to a body surface is called for or desirable.
- These applications include, for example, pressure-relieving cushions for application to a foot, wherein the cushions may or may not contain medication for transdermal or topical delivery, e.g., salicylic acid or the like.
- Such cushions will generally be comprised of a flexible, resilient outer layer, fabricated from a foam pad, fabric, or the like, with a layer of an adhesive composition of the invention laminated thereto for application to the skin surface.
- cohesive strength is important for the product to function as a pressure-relieving cushion, and the hydrophilic polymer should therefore be covalently crosslinked to a degree sufficient to impart the necessary cohesive strength.
- adhesives are in wound dressing products and other medical skin coverings such as adhesive tapes or the like.
- adhesive compositions may or may not be medicated; if medicated, they will generally contain anti-infective agents and/or other types of pharmacologically active agents.
- Medical skin coverings such as adhesive tapes and wound dressings may be readily fabricated using conventional manufacturing techniques, including the procedure described in U.S. Pat. No. 5,985,990, the disclosure of which is incorporated by reference herein.
- the adhesive compositions are also useful in conjunction with medical devices to be affixed to a body surface, diagnostic systems or devices to be affixed to a body surface, and any other application wherein adhesion to a body surface is necessary or desired.
- the present invention represents an important advance in the field of pressure sensitive adhesives, particularly bioadhesives.
- the novel adhesive compositions adhere well to hydrated surfaces such as mucosal tissue, are suitable for long-term skin contact and are nonirritating, noncomedogenic and nonsensitizing, are permeable to and physically and chemically compatible with a variety of drugs and drug types, and can enhance the rate at which an active agent migrates into a body surface.
- the present adhesive composition can be used in a variety of contexts, and can be readily tailored during manufacture with respect to hygroscopicity and the desired degree of hydrophilicity, adhesive and cohesive strength.
- Adhesive joint strength of the adhesive hydrogels to standard polyethylene (PE) film of 100 m in thickness was evaluated by a 180° peel test with an Instron 1221 Tensile Strength Tester at the peeling rate of 10 mm/min.
- a low-density PE film, crystallinity 45%, contact angle 105°, surface energy 28.5 mJ/m 2 was employed as a standard substrate.
- the adhesives were saturated with water by equilibrating in dessicators with a controlled pressure of water vapor of 50% at ambient temperature for 6-7 days. The time to attain a maximum strength of adhesive contact with the substrate was 15-20 min.
- the character of adhesive joint failure was observed with a TV camera interfaced to an IBM computer and photographed with a microscope. The locus of failure was ascertained by contact angle measurement of the detached substrate surface.
- Phase behavior of the hydrophilic polymers blends with PEG-400 over an entire compositional range was investigated by Differential Scanning Calorimetry (DSC) using a Mettler TA 4000/DSC-30 differential scanning calorimeter calibrated with indium and gallium.
- DSC Differential Scanning Calorimetry
- the samples were first quench cooled with liquid nitrogen from ambient temperature to ⁇ 100° C. over 2-3 minutes and then heated at a rate of 20° C. min ⁇ 1 to 220° C. Upon heating, a heat capacity jump followed by a single exotherm coupled with a symmetric endotherm, and a high temperature endotherm, were normally observed for the blends.
- Viscoelastic properties and the durability of adhesive joints of adhesive hydrogels were studied using a squeeze-recoil technique on a DTDM thermomechanical analyzer (microdilatometer) as described by Kotomin et al. (1999), “Squeeze-recoil analysis of adhesive hydrogels and elastomers” Polym Mater. Sci. Eng. 81:425-426 and Kotomin et al. (2000), “Durability and fracture of some viscoelastic adhesives” Proceed. 23 rd Adhesion Soc. Annual Meeting, Myrtle Beach, S.C., pp. 413-415.
- the polymer sample was placed between two flat silica surfaces formed by loading rod and supporting plate and subjected to the action of a fixed compressive load, followed by removing the compressive load to allow the sample relaxation.
- Table 2 reports the properties of PVP adhesive blends with PEG-400.
- Examples 1-4 and FIGS. 2 and 3 demonstrate the effect of PVP-PEG blend composition on adhesive properties.
- the relationship of adhesion to the phase behavior of PVP-PEG blends is also shown, described in terms of the negative T g deviation from the weight-average magnitudes ( ⁇ T g ), found with the Fox equation (1), and the ⁇ C p T g value.
- the adhesion appears in a narrow range of concentration.
- the maximum adhesion corresponds to the maximum ⁇ T g values and to the minimum ⁇ C p T g value.
- Examples 1, 5-9 and FIG. 4 reveal the impact of relative humidity (RH) of the surrounding atmosphere on the adhesive behavior of PVP-PEG blends.
- PVP is a hygroscopic polymer that absorbs more than 25% water upon exposure to a high RH ( FIG. 9 ).
- RH relative humidity
- PVP-overloaded blends having higher glass transition temperatures, where debonding proceeds through an adhesive mechanism, the blend hydration increased the force required to rupture adhesive bond.
- the effect of additional plasticizer reduces the adhesion.
- an adhesive remainder occurs at the substrate interface upon adhesive joint failure (Table 1).
- Examples 1, 10 and 11 exhibit the effects of the chain length of the hydrophilic polymer (PVP) on adhesive joint strength.
- peel strength of an adhesive joint tended to decrease with the reduction of molecular weight.
- Examples 12-16 demonstrate the impact of adhesive layer thickness upon adhesive joint strength. In accordance with Equation 2, the peel force required to rupture an adhesive joints was found to increase with the increase in thickness of the adhesive layer.
- the tacky blends can be obtained by mixing PVP with hydroxyl-terminated (Examples 17-41) or carboxyl terminated (Examples 42-47) short-chain plasticizers.
- Short-chain plasticizers include: ethylene glycol (Examples 17-19) and its polymers (PEG), ranging in molecular weight from 200 to 600 g/mol (Examples 20-23); low molecular weight 1,3- and 1,2-propylene glycol (PG) (Examples 24, 25); and alkane diols from propane diol up to pentane diols (PD) and hexane diol (HD) inclusive (Examples 27-39).
- Polypropylene glycol (PPG) has been found to be a good plasticizer for PVP, but does not develop any adhesion or tack (Example 26).
- the glass transition temperatures of plasticizers examined were within the range of ⁇ 59° C.
- the plasticizer has to be either amorphous or crystalline, but the melting temperature of appropriate plasticizers, T m , is normally lower than 50° C., the value found for 1,6-hexane diol (HD) (Examples 33-37).
- T m melting temperature of appropriate plasticizers
- the adhesive strength correlates with maximum ⁇ T g and minimum ⁇ C p T g values.
- the highest peel strength was found for PVP blends with glycerol (Example 41), which possesses a high density of hydroxyl groups per molecule. Strictly speaking, the carbonic diacids of Table 3 and Examples 44-47 are not acting as plasticizers but rather as noncovalent crosslinking agents and cohesive interaction enhancers.
- carbonic diacids can be employed in combination with plasticizers so as to reduce T g to the values inherent in PSAs.
- plasticizers For proper adhesion, carbonic diacids can be employed in combination with plasticizers so as to reduce T g to the values inherent in PSAs.
- Such approach has been used in a Plastoid adhesive blend (U.S. Pat. Nos. 5,730,999 and 5,993,849, EP 848960 A3), where EUDRAGIT E-100 was crosslinked by succinic acid and plasticized with tributylcitrate.
- Dry blends of PVP with 50% of carbonic diacids have been found to exhibit high T g values (28,-34,-43, and 24° C. for SA, MA, GA, and AA, respectively) and, therefore, develop no adhesion.
- the PEG-600 terminated by carboxyl groups (Examples 42, 43), serves as both a crosslinking agent and a plasticizer, imparting adhesion to PVP blends.
- PSA Compositions Prepared by Mixing Different Hydrophilic Polymers with Complementary Short-chain Plasticizers
- PVCap-PEG hydrogels exhibit a Lower Critical Solution Temperature (LCST) about 35° C. (see Kirsh Y E., Water soluble poly(N-vinylamides), Wiley, N.Y., 1998). Below this temperature the PVCap is easily soluble in water and behaves like moderately hydrophilic polymer, while above LCST the PVCap becomes insoluble in water hydrophobic polymer. This property is highly useful for the development of thermoresponsive or so-called “smart” adhesive hydrogels.
- LCST Critical Solution Temperature
- PNIPAM/PEG400 250,000 157 64 36 50 66 89.0 230 misc. 55.
- Luvisco173/PEG400 100,000 57.5 30 70 50 37.1 65.9 High** cohesive 62. 36 64 34.0 79.4 High** cohesive 63. Luvisco137/PEG400 100,000 29 17 83 50 9.3 138.7 High** cohesive 64.
- the adhesive hydrogels of the invention display a number of useful viscoelastic properties, similar to the properties of cured rubbers ( FIGS. 6-8 ).
- adhesive hydrogels are hydrophilic and water-soluble rubbers, featuring rubber-like elasticity as one of their major performance properties. Both the rubber-like elastic and viscous contributions to the rheology of the present adhesive hydrogels are illustrated by the data in FIG. 6 .
- the yield stress in the PVP-PEG adhesive hydrogel is associated with a critical magnitude of shear stress in the flow curve shown in FIG. 7 , at which the apparent shear viscosity climbs to infinity and the deformation rate drops tending to zero.
- the yield stress is an integral measure of cohesive strength, which has been shown to relate to the ⁇ f value in equation (2) and which determines the adhesive properties of an adhesive polymer (Feldstein et al. (2000), “Molecular insight into theological and diffusion determinants of pressure-sensitive adhesion,” Proceed. 23 rd Annual Meeting Adhesion Soc., pp. 54-56).
- the relaxation of polymer deformation occurs, termed the “retardation,” when deformation changes its sign and the polymer returns, more or less, to its initial shape.
- the adhesive hydrogel demonstrated ( FIG. 6 ) the instantaneous (Hooke's) retardation, followed by a creep recoil.
- the obtained Se magnitude corresponds to an average molecular weight of polymer chain between entanglements Mc ⁇ 130,000 g/mol, which is typical of slightly cross-linked rubbers, whereas the n value is a characteristic of highly dense network.
- the obtained S e and ⁇ values refer most likely to the contribution of network formed by the entanglements of PVP chains, while the n exponent relates to the contribution of the much more dense and faster relaxing H-bonded network.
- the superposition of the recoil compliance profiles for PVP-PEG hydrogel and PB rubber ( FIG. 8 ) provides evidence that the hydrogel retardation properties are typical of elastomers. Accordingly, the adhesive hydrogels described represent, in essence, water-soluble rubbers.
- Therapeutic agents were first dissolved in a mixture of PEG-400 (plasticizer) and ethyl alcohol (solvent). Upon complete drug dissolution, the PVP or another hydrophilic polymer was dissolved in the earlier prepared mixture, forming casting solution that was cast onto polyethylene terephthalate backing film of 0.02 mm in thickness and dried at temperatures of 20-60° C.
- In vitro drug delivery rate determination from water-soluble PSA matrices was performed using human cadaver skin or a skin-imitating Carbosil membrane to protect the matrices from dissolving in the receptor solution.
- the patch was adhered to the center of a Carbosil membrane sheet of twice its area.
- the membrane margins were then wrapped around the sample.
- the back side of the packet was closely attached to a steel plate-holder to prevent direct contact of the matrix with the receptor solution.
- cadaver skin epidermis can be used instead of a Carbosil membrane.
- the holder with the wrapped sample was then submerged into an aqueous sink and in vitro drug delivery rate was determined using a USP rotating cylinder method paddle-over-disc.
- the rate of drug appearance rate in a receptor solution (0.15 M NaCl) at 35.0 ⁇ 0.5° C. was determined spectrophotometrically.
- Drug permeability coefficients through skin epidermis (P s ) and a Carbosil membrane (P m ) were measured as the fluxes of drug delivered from the hydrophilic PSA matrix normalized by the drug concentration in the donor vehicle, taking the matrix density (1.10 ⁇ 0.12 g/cm 3 ) into account.
- compositions and properties of prepared therapeutic systems are presented in the Table 5.
- the hydrophilic PSA matrices based on both the PVP and PVCap blends with PEG-400 provide high delivery rates through both the skin-imitating Carbosil membrane and human skin epidermis.
- the hydrophilic PSA matrices allow us to enhance appreciably the rates of drug delivery compared to known hydrophobic PSAs such as PIB, PDMS and styrene-butadiene rubbers.
- the rates of drug delivery from the PVCap-PEG matrices are enhanced compared to the PVP-PEG matrix (compare examples 66 and 67, 71 and 72, 80 and 81).
- TDP topical dermal patch
- Example 82 refers to an antifungal topical dermal patch based on the PVP-PEG PSA matrix.
- the patch is composed of a nonocclusive cotton textile backing on one side of the drug-loaded PVP-PEG adhesive matrix and a protective layer on the other side, which is removed before patch application to the skin.
- the patch is designed for topical targeted treatment of mycosis and contains 3% of chinosol (8-hydroxyquinoline sulfate) as an antifungal agent.
- the salt form of the drug serves to reduce its percutaneous absorption into systemic circulation.
- in vivo chinosol release rate from the Chinosive TDP in human volunteers averages only 0.42 ⁇ g/cm 2 h as has been evaluated from the drug remainder in the patch removed from the skin.
- the topical antifungal monotherapy with the chinosol-containing patch results in essential acceleration of the treatment compared to the control group treated by the clotrimazol.
- hydrophilic PSA matrices outlined by this invention provide the performance properties useful in application dosage forms designed for transdermal and dermal drug delivery.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- Adhesive: High tack coupled with an optimum slip-stick transition point.
- Transport: Drug release kinetics controlled in terms of transdermal delivery rate and the functional lifetime of device.
- Reservoir: Drug compatibility and ability to be stored in a stable form tailored to the incorporated drug of interest.
- Biological: No toxicity, skin irritation and sensitization.
Such diverse requirements are difficult to combine in a single system.
-
- 1. Hydrophilic adhesives can provide greater adhesion compared with hydrophobic adhesives, because the surface energy of hydrophilic adhesives is typically higher and closer to that of biological substrates such as skin and mucosal membranes.
- 2. Hydrophilic adhesives are compatible with a wide variety of drugs, excipients and additives.
- 3. The plasticizing effect of water sorbed by hydrophilic adhesives from hydrated skin or mucosal tissues enhances adhesion, in contrast to hydrophobic adhesives.
- 4. The enhanced solubility of drugs in hydrophilic adhesives facilitates control over drug release kinetics.
- 5. With hydrophilic adhesives, based on hydrophilic polymers, there is an expanded capability to control and manipulate the adhesive-cohesive balance.
- 6. The adhesive properties of hydrophilic polymers are considerably less sensitive to their molecular weight than those of hydrophobic polymers, as a result of specific intramolecular and intermolecular interaction within hydrophilic adhesives.
-
- (a) preparing a plurality of compositions each comprised of a hydrophilic polymer having a glass transition temperature Tg pol admixed with a plasticizer having a glass transition temperature Tg pl and capable of covalently or noncovalently crosslinking the hydrophilic polymer, wherein the weight fraction of the hydrophilic polymer in each composition is wpol, and the weight fraction of the plasticizer in each composition is wpl;
- (b) calculating predicted glass temperatures Tg predicted for each composition using the Fox equation (1)
and plotting Tg predicted versus wpl, for each composition;
-
- (c) determining the glass transition temperature Tg actual for each composition, and plotting Tg actual versus wpl, for each composition;
- (d) identifying the region of the plots of (b) and (c) wherein Tg actual is less than Tg predicted; such that there is a negative deviation from Tg predicted;
- (e) within the region identified in (d), identifying the optimum weight of plasticizer wpl optimum at which the negative deviation from Tg predicted is at a maximum; and
- (f) admixing a monomeric precursor to the hydrophilic polymer and the plasticizer under polymerizing conditions to provide an adhesive composition having an optimized degree of adhesion, wherein the weight fraction of plasticizer in the composition is wpl optimums and the weight fraction of the hydrophilic polymer in the composition is 1-wpl optimum.
-
- (a) preparing a plurality of compositions each comprised of a hydrophilic polymer having a glass transition temperature Tg pol admixed with a plasticizer having a glass transition temperature Tg pl and capable of covalently or noncovalently crosslinking the hydrophilic polymer, wherein the weight fraction of the hydrophilic polymer in each composition is wpol, and the weight fraction of the plasticizer in each composition is wpl, such that wpol is equal to 1-wpl;
- (b) calculating predicted glass temperatures Tg predicted for each composition using the Fox equation (1)
and plotting Tg predicted versus wpl for each composition;
-
- (c) determining the glass transition temperature Tg actual for each composition, and plotting Tg actual versus wpl for each composition;
- (d) identifying the region of the plots of (b) and (c) wherein Tg actual has a predetermined deviation from Tg predicted; and
- (e) admixing a monomeric precursor to the hydrophilic polymer and the plasticizer under polymerizing conditions to provide an adhesive composition having a predetermined degree of adhesion, wherein the weight percent of plasticizer in the composition corresponds to a value within the region identified in section (d).
-
- (A) a drug reservoir comprising (1) a substantially non-aqueous pressure sensitive adhesive matrix of a hydrophilic polymer having a glass transition temperature Tg pol, and a complementary hydroxyl-terminated or carboxyl-terminated short-chain plasticizing agent having a glass transition temperature Tg pl and capable of hydrogen bonding or electrostatic bonding to the hydrophilic polymer, wherein the weight ratio of hydrophilic polymer to complementary short-chain plasticizing agent is selected so to provide a predetermined deviation in (a) the actual glass transition temperature Tg actual of the composition from (b) the predicted grass transition temperature Tg predicted for the composition calculated using the Fox equation, and (2) a therapeutically effective amount of the active agent; and
- (B) a backing layer laminated to the drug reservoir that serves as the outer surface of the device during use.
where Tg predicted is the predicted glass transition temperature of the hydrophilic polymer/plasticizer composition, wpol is the weight fraction of the hydrophilic polymer in the composition, wpl is the weight fraction of the plasticizer in the composition, Tg pol is the glass transition temperature of the hydrophilic polymer, and Tg pl is the glass transition temperature of the plasticizer. The inventors herein have now discovered that an adhesive composition having an optimized (e.g., maximized) degree of adhesion can be prepared from a hydrophilic polymer and a complementary plasticizer by selecting the components and their relative amounts to give a predetermined deviation from Tg predicted, even if each component individually is non-tacky. Generally, the predetermined deviation from Tg predicted will be the maximum negative deviation, such that this is the point where adhesive strength is maximized.
TABLE 1 |
Glass transition characteristics of representative polymers. |
ΔCpTg | ||||
Polymer | Tg, K | ΔCp, J/gK | J/ | |
Polydimethylsiloxane | ||||
150 | 0.30 | 45.0 | ||
|
200 | 0.40 | 79.6 | |
|
200 | 0.46 | 92.0 | |
Polyethylene | 237 | 0.39 | 92.5 | |
PEG - 400 | 200 | 0.51 | 101.4 | |
Bisphenol polycarbonate | 415 | 0.25 | 103.9 | |
Polymethyl methacrylate | 385 | 0.29 | 112.8 | |
Poly(N-vinyl pyrrolidone) | 449 | 0.27 | 121.2 | |
Polypropylene | 253 | 0.55 | 139.2 | |
Polystyrene | 375 | 0.38 | 141.0 | |
Polyvinyl acetate | 305 | 0.50 | 153.4 | |
Polyethylene terephthalate | 340 | 0.49 | 165.7 | |
Polyvinyl chloride | 355 | 0.63 | 229.9 | |
where b is the width and l the thickness of the adhesive layer, a is a size of diffusing polymer segment, N is Avogadro's number, τ is a segmental relaxation time and σf is a critical stress at adhesive polymer fracture under detaching tensile force. Equation (2) establishes a general relation of adhesive strength to the measures of molecular mobility (D) and cohesive toughness (σf) of PSA polymer.
where fg is the fractional free volume of PVP at Tg, Δα is the thermal expansion coefficient for PEG and φ is polymer volume fraction in the blend. The fg factor has been found to be of the same universal magnitude, about 0.025, for all polymers (see Ferry (1970). Viscoelastic Properties of Polymers, 2nd Ed., Wiley: N.Y., Chapter 11). The Kovacs equation (3) manifests theoretically that the specific behavior of a PVP-PEG system is due to the PEG properties. Actually, no other factors relating to PVP, except for the universal fg value (which, again, is of a common magnitude for different polymers), control the blend Tg. Thus, the validity of the Kovacs equation for the PVP-PEG system implies that the difference between the Tgs of a hydrophilic polymer and a short-chain complementary plasticizer should be larger than 50° C. in order for pressure-sensitive adhesion to appear upon blending the polymer and plasticizer.
TABLE 2 |
Adhesive properties and phase behavior of PVP blends with PEG-400/ |
PVP | Composition, wt % | Thickness | ΔCpTg, | Peel | Debonding |
No. | MW | PVP | PEG-400 | RH, % | (μm) | ΔTg, K | J/g | Force, N/ | mode | |
1. | 1,000,000 | 64 | 36 | 50 | 130 | 71 | 46.2 | 370 | misc. |
2. | 73 | 27 | 39 | 119.0 | 83 | adhesive | |||
3. | 54 | 46 | 65.2 | 92.6 | 95 | cohesive | |||
4. | 47 | 53 | 37.2 | 77.2 | 64 | cohesive | |||
5. | 64 | 36 | 20 | 130 | 69 | 30 | adhesive | ||
6. | 40 | 73 | 90 | adhesive | |||||
7. | 65 | 70.5 | 59.1 | 330 | cohesive | ||||
8. | 80 | 66.2 | 42 | cohesive | |||||
9. | 90 | 77 | 96.0 | — | cohesive | ||||
10. | 150,000 | 64 | 36 | 50 | 130 | 82.0 | 15 | cohesive | |
11. | 8,000 | 87.5 | 0 | cohesive | |||||
12. | 1,000,000 | 64 | 36 | 50 | 250 | 390 | misc. | ||
13. | 175 | 390 | misc. | ||||||
14. | 119 | 330 | adhesive | ||||||
15. | 70 | 210 | adhesive | ||||||
16. | 50 | 185 | adhesive | ||||||
TABLE 3 |
Adhesive and phase properties of PVP blends with short-chain plasticizers |
Composition, wt. % | ΔCpTg, | Peel Force, | Debonding |
No. | Plasticizer | Tg, ° C. | Tm, ° C. | Plasticizer | PVP | −ΔTg, K | J/g | N/m | mode |
17. | Ethylene glycol | −112 | 25 | 75 | n/d | n/d | 123 | adhesive | |
18. | 36 | 64 | 60 | 62.0 | 142 | adhesive | |||
19. | 45 | 55 | n/d | n/d | 127 ± 15 | adhesive | |||
20. | PEG-200 | −70 | n/a | 36 | 64 | 82 | 195 | cohesive | |
21. | PEG-300 | −70 | n/a | 75 | 110 | adhesive | |||
22. | PEG-600 | −70 | 16 | 68 | 75.3 | 15 | adhesive | ||
23. | PEG-1000 | −70 | 39 | 60 | 22.71 | 0 | — | ||
24. | 1,3-Propylene | −116 | n/a | 35 | 65 | 55 | 47.9 | 116 ± 10 | adhesive |
Glycol | |||||||||
25. | 1,2-Propylene | −95 | n/a | 35 | 65 | 42 | 56.5 | 180 ± 20 | adhesive |
Glycol | |||||||||
26. | PPG-425 | −68 | n/a | 34 | 66 | 75 | 68.3 | 0 | — |
27. | 1,5-PD | −104 | −12.5 | 43 | 57 | 0 | 47.1 | 0 | — |
28. | 50 | 50 | 55 | 72.6 | 30 | cohesive | |||
29. | 66.5 | 33.5 | 32.5 | 105.0 | 10 | cohesive | |||
30. | 2,4-PD | −59 | n/a | 32 | 68 | 02 | 59.7 | 0 | adhesive |
31. | 49 | 51 | 65.4 | 89.0 | 190 | adhesive | |||
32. | 65.5 | 34.5 | 39.5 | 140.1 | 0 | cohesive | |||
33. | 1,6-HD | −99 | 49.1 | 33 | 67 | 27.4 | 29.32 | 0 | — |
34. | 37.6 | 62.4 | 83.1 | 59.6 | 11 | cohesive | |||
35 | 45 | 55 | 64.6 | cohesive | |||||
36. | 50 | 50 | 55.6 | 58.6 | 19 | cohesive | |||
37. | 66.6 | 33.4 | 38.5 | 101.0 | 0 | cohesive | |||
38. | 2,5-HD | −62 | n/a | 49 | 51 | 65.32 | 76.4 | 26 | adhesive |
39. | 66 | 34 | 40.1 | 122.2 | 10 | cohesive | |||
40. | Glycerol | −74 | n/a | 23.4 | 76.6 | 138.1 | 45.92 | — | adhesive |
41. | 38 | 62 | 70.5 | 85.7 | 850 | misc. | |||
42. | Carboxyl-terminated | −49 | 12 | 36 | 64 | 752 | 55.9 | 8.5 | adhesive |
43. | PEG-600 | 50 | 50 | 55 | 112 | 346.5 ± 15 | cohesive | ||
44. | Succinic acid (SA) | n/d | 188 | 50 | 50 | n/d | 26.1/75.03 | 0/62 | adhesive |
45. | Malonic acid (MA) | n/d | 135 | 50 | 50 | n/d | 52.5/80.13 | 7.6/71 | adhesive |
46. | Glutaric acid (GA) | n/d | 96 | 50 | 50 | n/d | 129/853 | 0/94 | adhesive |
47. | Adipic acid (AA) | n/d | 152 | TBD | TBD | n/d | 58.1/893 | TBD | adhesive |
1TheΔCp value has been found to be decreased due to a high degree of blend crystallinity. | |||||||||
2The blend is inhomogeneous. Two glass transitions are observed. The data relate to the lower glass transition temperature. | |||||||||
3The data refer to dry blends and those containing 25% of water, respectively. |
TABLE 4 |
Adhesive properties of PEG-400 miscible blends with various hydrophilic polymers. |
Polymer/ | Polymer | Composition, wt. % | RH, | −ΔTg, | ΔCpTg, | Peel Force | Debond. |
No. | Plasticizer | MW | Tg, ° C. | Polymer | Plasticizer | % | K | J/g | N/m | mode |
48. | PVCap/PEG-400 | 100,000 | 165 | 64 | 36 | 40 | 71 | 88.3 | 533 | misc. |
49. | 50 | 363 | cohesive | |||||||
50. | 60 | 300 | cohesive | |||||||
51. | 80 | 23 | cohesive | |||||||
52. | PVCap/PEG400 | 1,000,000 | 197 | 64 | 36 | 50 | 81 | 98.0 | 150 | adhesive |
53. | PVAA/PEG400 | 1,000,000 | 64 | 36 | 50 | 397 | adhesive | |||
54. | PNIPAM/PEG400 | 250,000 | 157 | 64 | 36 | 50 | 66 | 89.0 | 230 | misc. |
55. | PMAA*/PEG400 | 150,000 | 36 | 64 | 50 | — | — | 0 | — | |
56. | 47 | 53 | — | — | 27.5 ± 5 | adhesive | ||||
57. | 63 | 37 | — | — | 72 | cohesive | ||||
58. | PAA/PEG400 | 150,000 | 47 | 53 | 50 | 51 | adhesive | |||
59. | PMAA*/1,5 PD | 150,000 | 36 | 64 | 50 | — | — | 0 | — | |
60. | 50 | 50 | — | — | 22.3 | adhesive | ||||
61. | Luvisco173/PEG400 | 100,000 | 57.5 | 30 | 70 | 50 | 37.1 | 65.9 | High** | cohesive |
62. | 36 | 64 | 34.0 | 79.4 | High** | cohesive | ||||
63. | Luvisco137/PEG400 | 100,000 | 29 | 17 | 83 | 50 | 9.3 | 138.7 | High** | cohesive |
64. | 36 | 64 | 24.4 | 180.1 | High** | cohesive | ||||
*PMAA exhibits no glass transition; therefore, the negative deviation from weight-average magnitudes cannot be evaluated. | ||||||||||
**Adhesion is very strong, but cannot be measured because the blend provides an inseparable adhesive joint with siliconized release liner. |
where S(t) is recoil compliance and Se is the equilibrium tensile compliance, t=time, τ is a characteristic (retardation) time, n denotes a Chasset-Thirion exponent. Computer simulation of the recoil function kinetic profiles in
TABLE 5 |
Properties of drug-loaded hydrophilic matrices. |
Drug content | Delivery rate in vitro | |||||
Matrix | in the matrix | μg/cm2h across: | Pm (104) | Ps (104) |
Drug | composition | (%) | Carbosil | Human skin | cm/h | cm/h | |
65. | Anabasine | PVP-PEG | 1.6 | 150 ± 20 | 106.3 ± 12.0 | ||
66. | Isosorbide | PVP-PEG | 9.6 | 384 ± 48 | 13.0 ± 4.3 | 44 ± 5 | 1.5 ± 0.5 |
dinitrate | |||||||
67. | Isosorbide | PVCap-PEG | 9.6 | 411 ± 49 | 47.1 ± 5 | ||
dinitrate | |||||||
68. | Aminostigmine | PVP-PEG | 14.3 | 625 ± 20 | 33.7 ± 12.0 | ||
7.6 | 263 ± 10 | ||||||
4.0 | 65 ± 5 | ||||||
69. | Glyceryl | PVP-PEG | 7.3 | 160 ± 40 | 12.4 ± 4.0 | 25.6 ± 1.4 | 1.9 ± 0.5 |
trinitrate | 1.9 | 45 ± 12 | |||||
70. | Verapamil | PVP-PEG | 39.1 | 110 ± 20 | 21.4 ± 1.5 | 0.4 ± 0.1 | |
24.3 | 110 ± 16 | ||||||
13.8 | 95 ± 19 | 6 ± 2 | |||||
3.9 | 78 ± 6 | ||||||
71. | Propranolol | PVP-PEG | 13.8 | 118 ± 25 | 26.0 ± 15.0 | 10.6 ± 1.1 | 2.1 ± 0.2 |
7.4 | 79 ± 6 | ||||||
72. | Propranolol | PVCap-PEG | 13.8 | 145 ± 30 | 13.0 ± 1.9 | ||
73. | Silabolin | PVP-PEG | 13.9 | 131 ± 30 | 10.3 ± 0.5 | ||
10.8 | 107 ± 21 | ||||||
7.2 | 65 ± 14 | ||||||
74. | Foridone | PVP-PEG | 13.8 | 37.3 ± 4.5 | 4.2 ± 1.5 | ||
10.8 | 34.1 ± 4.0 | ||||||
7.4 | 24.8 ± 3.0 | ||||||
3.1 | 20.6 ± 1.9 | ||||||
75. | Clonidine | PVP-PEG | 7.7 | 26.8 ± 0.8 | 0.75 ± 0.04 | 4.0 ± 1.1 | 0.6 ± 0.2 |
1.4 | 5 ± 2 | 0.78 ± 0.1 | |||||
76. | Cytisine | PVP-PEG | 7.4 | 21 ± 3 | 9.0 ± 4.0 | 3.0 ± 0.5 | 1.3 ± 0.5 |
77. | Phenazepam | PVP-PEG | 7.4 | 11 ± 2 | 1.4 ± 0.3 | ||
6.8 | 7 ± 2 | ||||||
78. | Nifedipin | PVP-PEG | 15.4 | 19 ± 3 | 1.3 ± 0.2 | ||
79. | Fluacizin | PVP-PEG | 13.8 | 5 ± 1 | 6 ± 2 | 0.4 ± 0.1 | 0.4 ± 0.1 |
80. | Salbutamol | PVP-PEG | 13.8 | 0.10 ± 0.04 | 0.003 | ||
81. | Salbutamol | PVCap-PEG | 13.8 | 4.9 ± 1 | 0.4 ± 0.1 | ||
82. | Chinosol | PVP-PEG | 3.0 | n/a | n/a | n/a | n/a |
As follows from the data in Table 5, the hydrophilic PSA matrices based on both the PVP and PVCap blends with PEG-400 (36 wt. % of the plasticizer in the blends) provide high delivery rates through both the skin-imitating Carbosil membrane and human skin epidermis. As comparative data in the Table 6 indicate, the hydrophilic PSA matrices allow us to enhance appreciably the rates of drug delivery compared to known hydrophobic PSAs such as PIB, PDMS and styrene-butadiene rubbers. In turn, the rates of drug delivery from the PVCap-PEG matrices are enhanced compared to the PVP-PEG matrix (compare examples 66 and 67, 71 and 72, 80 and 81).
TABLE 6 |
Comparative study of in vitro drug delivery rates (μg/cm2h) from the |
hydrophilic PVP-PEG matrix and conventional hydrophobic matrices |
Delivery rate | |||
from hydrophilic | Release rate | Composition | |
matrix via | from hydrophobic | of hydrophobic | |
Drug | Carbosil | matrices | matrix |
Aminostigmine | 625 ± 20 | 8 ± 1 | Styrene |
rubber | |||
Nitroglycerin | |||
160 ± 40 | 80 ± 10 | PDMS, | |
(Nitroderm ® | |||
TTS) | |||
Silabolin | 131 ± 30 | 16 ± 7 | Styrene butadiene |
rubber | |||
Propranolol | 118 ± 25 | 56 ± 4 | Styrene |
rubber | |||
Clonidine | |||
5 ± 2 | 1.6 ± 0.2 | PIB (Catapress ® | |
TTS) | |||
Claims (122)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/761,118 USRE45666E1 (en) | 2000-07-07 | 2013-02-06 | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21638600P | 2000-07-07 | 2000-07-07 | |
US84753201A | 2001-05-01 | 2001-05-01 | |
US11/150,811 USRE44145E1 (en) | 2000-07-07 | 2005-06-10 | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
US13/761,118 USRE45666E1 (en) | 2000-07-07 | 2013-02-06 | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/900,697 Reissue US6576712B2 (en) | 2000-07-07 | 2001-07-06 | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE45666E1 true USRE45666E1 (en) | 2015-09-08 |
Family
ID=47999402
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/150,811 Expired - Lifetime USRE44145E1 (en) | 2000-07-07 | 2005-06-10 | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
US13/761,118 Expired - Lifetime USRE45666E1 (en) | 2000-07-07 | 2013-02-06 | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/150,811 Expired - Lifetime USRE44145E1 (en) | 2000-07-07 | 2005-06-10 | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
Country Status (1)
Country | Link |
---|---|
US (2) | USRE44145E1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150080437A1 (en) | 2013-09-17 | 2015-03-19 | Corium International, Inc. | Topical adhesive composition, and device, for improving aesthetic appearance of skin |
Citations (322)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2561071A (en) | 1949-09-21 | 1951-07-17 | Prisk Howard Conley | Holder for subcutaneous administration of medicaments |
US2579403A (en) | 1950-06-01 | 1951-12-18 | Slomowitz Julius | Medical bandage |
US3150977A (en) | 1959-12-23 | 1964-09-29 | Gevaert Photo Prod Nv | Light-sensitive photographic materials |
GB1108837A (en) | 1965-11-30 | 1968-04-03 | Astra Pharma Prod | Improvements in material for causing local anaesthesia |
US3689439A (en) | 1968-06-12 | 1972-09-05 | Gaf Corp | Process for preparing a crosslinked porous polyvinyl pyrrolidone granule |
US3721657A (en) | 1969-07-28 | 1973-03-20 | M Seiderman | Hydrophilic gel polymers of vinylpyrrolidine and hydroxyalkyl methacrylate |
US3749755A (en) | 1969-12-22 | 1973-07-31 | Basf Ag | Thermoplastic molding compositions of high impact resistance |
US3852228A (en) | 1971-01-07 | 1974-12-03 | D Brothers | Thixotropic coating composition |
US3957605A (en) | 1973-09-10 | 1976-05-18 | Union Carbide Corporation | Process for radiation cocrosslinking water soluble polymers and products thereof |
US3993551A (en) | 1973-09-10 | 1976-11-23 | Union Carbide Corporation | Process for cocrosslinking water soluble polymers and products thereof |
US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
US4091090A (en) | 1974-07-08 | 1978-05-23 | Johnson & Johnson | Potentiated anesthetics |
US4093673A (en) | 1974-11-14 | 1978-06-06 | Ppg Industries, Inc. | Coating compositions composed of hydroxyfunctional polymers or copolymers and alkoxysilanes |
US4160020A (en) | 1975-11-24 | 1979-07-03 | Alza Corporation | Therapeutic device for osmotically dosing at controlled rate |
US4231369A (en) | 1977-05-24 | 1980-11-04 | Coloplast International A/S | Sealing material for ostomy devices |
US4277580A (en) | 1978-05-22 | 1981-07-07 | Texaco Inc. | Terpolymer of N-vinyl pyrrolidone in alkoxylated form |
US4325851A (en) | 1980-10-24 | 1982-04-20 | Herman Colon | Water-activatable hot-melt adhesives |
US4346709A (en) | 1980-11-10 | 1982-08-31 | Alza Corporation | Drug delivery devices comprising erodible polymer and erosion rate modifier |
US4367732A (en) | 1980-12-05 | 1983-01-11 | Coloplast A/S | Skin barrier |
JPS58162681U (en) | 1982-04-22 | 1983-10-29 | ソニー株式会社 | Electrical equipment operating device |
JPS59196817A (en) | 1983-04-21 | 1984-11-08 | Sekisui Chem Co Ltd | Application drug |
US4492685A (en) | 1979-08-14 | 1985-01-08 | Key Pharmaceuticals, Inc. | Protective skin matrix |
DE8509793U1 (en) | 1985-04-02 | 1985-05-15 | Allpack Industrielle Lohnverpackung GmbH & Co KG, 7050 Waiblingen | Pharmaco adhesive plaster |
US4529601A (en) | 1977-12-01 | 1985-07-16 | Astra Lakemedel Aktiebolag | Local anesthetic mixture for topical application and method for obtaining local anesthesia |
US4552751A (en) | 1980-10-17 | 1985-11-12 | Ono Pharmaceutical Co., Ltd. | Long-lasting multi-layered film preparation |
US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4587289A (en) | 1982-09-27 | 1986-05-06 | Ahmet Comert | Adhesive thermoplastic compositions |
US4593053A (en) | 1984-12-07 | 1986-06-03 | Medtronic, Inc. | Hydrophilic pressure sensitive biomedical adhesive composition |
US4624665A (en) | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4699146A (en) | 1982-02-25 | 1987-10-13 | Valleylab, Inc. | Hydrophilic, elastomeric, pressure-sensitive adhesive |
US4713243A (en) | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
US4743249A (en) | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
US4750482A (en) | 1982-02-25 | 1988-06-14 | Pfizer Inc. | Hydrophilic, elastomeric, pressure-sensitive adhesive |
US4771105A (en) | 1986-02-05 | 1988-09-13 | Sekisui Kaseihin Kogyo Kabushiki Kaisha | Water-absorbent resin and process for producing the same |
EP0303445A1 (en) | 1987-08-13 | 1989-02-15 | Walton S.A. | Clebopride transdermal patch |
WO1989003859A1 (en) | 1987-10-23 | 1989-05-05 | Vsesojuzny Nauchno-Issledovatelsky Institut Biotek | Composition of polymer diffusion matrix for transdermally introducing pharmaceutical substances |
JPH01151524A (en) | 1988-11-10 | 1989-06-14 | Yamanouchi Pharmaceut Co Ltd | 'satotsu-ko' poultice and preparation thereof |
US4849224A (en) | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4863970A (en) | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
US4863738A (en) | 1987-11-23 | 1989-09-05 | Alza Corporation | Skin permeation enhancer compositions using glycerol monooleate |
US4867748A (en) | 1986-10-17 | 1989-09-19 | Coloplast A/S | Dressing with hydrocolloid |
US4871536A (en) | 1982-06-17 | 1989-10-03 | L'oreal | Composition based on cationic polymers, anionic polymers and waxes for use in cosmetics |
US4873299A (en) | 1986-03-21 | 1989-10-10 | Basf Aktiengesellschaft | Batchwise preparation of crosslinked, finely divided polymers |
US4877628A (en) | 1987-09-03 | 1989-10-31 | International Flavors & Fragrances Inc. | Process for preparing a coated food product |
US4904247A (en) | 1984-08-31 | 1990-02-27 | Kendall Company | Pressure-sensitive hydrophilic laminate structures for use in wound dressing, transdermal and topical drug delivery |
US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US4927408A (en) | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
US4945084A (en) | 1987-07-08 | 1990-07-31 | Norman Oksman | Method and composition for topically treating anorectal or other dermal wounds |
US4953053A (en) | 1989-01-31 | 1990-08-28 | Harnischfeger Corporation | Method and apparatus for detecting mechanical overload of a hoist |
US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
US4983395A (en) | 1987-11-12 | 1991-01-08 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US5053227A (en) | 1989-03-22 | 1991-10-01 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
US5057500A (en) | 1990-02-12 | 1991-10-15 | Dermatologic Research Corporation | Treatment of pruritis with esters and amides |
JPH0366612B2 (en) | 1982-06-29 | 1991-10-18 | Shimadzu Corp | |
JPH03247334A (en) | 1990-02-26 | 1991-11-05 | Sumitomo Rubber Ind Ltd | Cold insulant |
JPH03275619A (en) | 1990-03-23 | 1991-12-06 | Nitsusui Seiyaku Kk | External agent composition |
US5073381A (en) | 1988-08-15 | 1991-12-17 | University Of Akron | Amphiphilic networks |
US5102662A (en) | 1989-12-08 | 1992-04-07 | Dow Corning Corporation | Insect repellent plastic |
US5125894A (en) | 1990-03-30 | 1992-06-30 | Alza Corporation | Method and apparatus for controlled environment electrotransport |
US5133970A (en) | 1989-07-24 | 1992-07-28 | Rohm Gmbh Chemische Fabrik | Water-soluble pressure-sensitive skin-adhesive and use thereof |
US5141750A (en) | 1986-06-13 | 1992-08-25 | Alza Corporation | Delayed onset transdermal delivery device |
JPH04266818A (en) | 1991-02-21 | 1992-09-22 | Sekisui Chem Co Ltd | Tacky agent for medical application |
EP0516026A1 (en) | 1991-05-28 | 1992-12-02 | Takeda Chemical Industries, Ltd. | Hydrogel and method of producing same |
US5173302A (en) | 1990-09-28 | 1992-12-22 | Medtronic, Inc. | Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs |
US5183901A (en) | 1992-01-24 | 1993-02-02 | Isp Investments Inc. | Urea-hydrogen peroxide-polyvinylpyrrolidone |
WO1993002717A1 (en) | 1991-08-09 | 1993-02-18 | Smith & Nephew Plc | Adhesive products |
US5196405A (en) | 1987-07-08 | 1993-03-23 | Norman H. Oskman | Compositions and methods of treating hemorrhoids and wounds |
US5200190A (en) | 1988-10-11 | 1993-04-06 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Percutaneous pharmaceutical preparation |
US5206385A (en) | 1992-01-24 | 1993-04-27 | Isp Investments Inc. | Urea-hydrogen peroxide-polyvinylpyrrolidone process |
US5224928A (en) | 1983-08-18 | 1993-07-06 | Drug Delivery Systems Inc. | Mounting system for transdermal drug applicator |
US5232702A (en) | 1991-07-22 | 1993-08-03 | Dow Corning Corporation | Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices |
US5234957A (en) | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5234690A (en) | 1991-08-23 | 1993-08-10 | Cygnus Therapeutic Systems | Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset |
US5240995A (en) | 1989-02-09 | 1993-08-31 | Alza Corporation | Electrotransport adhesive |
US5254346A (en) | 1988-02-23 | 1993-10-19 | Tucker Mark J | Occlusive body for administering a physiologically active substance |
US5270358A (en) | 1989-12-28 | 1993-12-14 | Minnesota Mining And Manufacturing Company | Composite of a disperesed gel in an adhesive matrix |
US5276079A (en) | 1991-11-15 | 1994-01-04 | Minnesota Mining And Manufacturing Company | Pressure-sensitive poly(n-vinyl lactam) adhesive composition and method for producing and using same |
WO1994005340A1 (en) | 1992-08-27 | 1994-03-17 | Coloplast A/S | A dressing for dosing one or more medicaments |
US5296512A (en) | 1989-04-26 | 1994-03-22 | Rohm Gmbh Chemische Fabrik | Water-soluble pressure-sensitive skin adhesive, its use, and agents provided with it |
US5300291A (en) | 1988-03-04 | 1994-04-05 | Noven Pharmaceuticals, Inc. | Method and device for the release of drugs to the skin |
US5310563A (en) | 1991-10-25 | 1994-05-10 | Colgate-Palmolive Company | Dental material and method for applying preventative and therapeutic agents |
US5322689A (en) | 1992-03-10 | 1994-06-21 | The Procter & Gamble Company | Topical aromatic releasing compositions |
US5326685A (en) | 1991-02-13 | 1994-07-05 | Gaglio Thomas J | Viscous fluid dispensing apparatus |
US5332576A (en) | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
DE4219368C2 (en) | 1992-06-12 | 1994-07-28 | Lohmann Gmbh & Co Kg | Electrically conductive transparent pressure sensitive adhesive films, process for their production and use for the production of biomedical electrodes |
US5338490A (en) | 1991-11-15 | 1994-08-16 | Minnesota Mining And Manufacturing Company | Two-phase composites of ionically-conductive pressure-sensitive adhesive, biomedical electrodes using the composites, and methods of preparing the composite and the biomedical electrodes |
US5342623A (en) | 1986-09-12 | 1994-08-30 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US5354823A (en) | 1993-08-09 | 1994-10-11 | Isp Investments Inc. | Films and extrusions of cured crosslinked vinyl lactam polymer and method of preparation |
US5362420A (en) | 1991-11-15 | 1994-11-08 | Minnesota Mining And Manufacturing Company | Low impedance pressure sensitive adhesive composition and biomedical electrodes using same |
JPH06100467B2 (en) | 1989-02-06 | 1994-12-12 | 株式会社シ−エックスア−ル | Proximity sensor |
EP0371421B1 (en) | 1988-11-28 | 1994-12-21 | The B.F. Goodrich Company | Crosslinked polyacrylic acid |
US5376377A (en) | 1990-10-29 | 1994-12-27 | Alza Corporation | Transdermal contraceptive formulations, methods and devices |
US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US5438076A (en) | 1988-05-03 | 1995-08-01 | Perio Products, Ltd. | Liquid polymer composition, and method of use |
US5446070A (en) | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5456745A (en) | 1988-08-13 | 1995-10-10 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Flexible, hydrophilic gel film, the process for its production and the use of it |
US5462745A (en) | 1986-09-12 | 1995-10-31 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US5462743A (en) | 1992-10-30 | 1995-10-31 | Medipro Sciences Limited | Substance transfer system for topical application |
EP0581581A3 (en) | 1992-07-29 | 1996-01-17 | Johnson & Johnson Consumer | Bioadhesive treatment compositions and methods of use |
US5492943A (en) | 1994-06-20 | 1996-02-20 | Hollister Incorporated | Adhesive skin barrier composition for ostomy appliance |
US5508024A (en) | 1992-05-22 | 1996-04-16 | International Research And Development Corp. | Topical antiperspirant composition consisting essentially of non-toxic water-insoluble occlusive film-forming antiperspirant polymer |
US5508367A (en) | 1993-11-29 | 1996-04-16 | Adhesives Research, Inc. | Water-soluble pressure sensitive adhesive |
EP0545594B1 (en) | 1991-11-22 | 1996-05-01 | Colgate-Palmolive Company | Oral composition having improved tooth whitening effect |
US5527271A (en) | 1994-03-30 | 1996-06-18 | Bristol-Myers Squibb Co. | Thermoplastic hydrogel impregnated composite material |
WO1996019205A1 (en) | 1994-12-21 | 1996-06-27 | Theratech, Inc. | Transdermal delivery system with adhesive overlay and peel seal disc |
US5543148A (en) | 1994-07-12 | 1996-08-06 | Combe, Incorporated | Stick delivery system for topical application of a treatment agent |
US5563153A (en) | 1995-02-22 | 1996-10-08 | University Of Kansas Medical Center | Sterile topical anesthetic gel |
EP0737477A1 (en) | 1993-12-27 | 1996-10-16 | Akzo Nobel N.V. | Percutaneously absorbable preparation |
US5575654A (en) | 1992-11-24 | 1996-11-19 | Fontenot; Mark G. | Apparatus and method for lightening teeth |
US5594068A (en) | 1993-05-28 | 1997-01-14 | Eastman Chemical Company | Cellulose ester blends |
US5593686A (en) | 1984-03-01 | 1997-01-14 | Sandoz Ltd. | Pharmaceutical compositions |
US5599373A (en) | 1988-09-30 | 1997-02-04 | F.P.S.- Finances Products Services, S.R.L. | Sulfur-based chemical soil-corrective in the form of pellets for agricultural use |
US5614178A (en) | 1992-07-28 | 1997-03-25 | The Procter & Gamble Company | Compositions for topical delivery of drugs comprising a mixture of high and low HLB surfactants and alkoxylated ether |
WO1997011676A1 (en) | 1995-09-25 | 1997-04-03 | Robert Eric Montgomery | Tooth bleaching compositions |
US5631267A (en) | 1993-02-02 | 1997-05-20 | Mayo Foundation For Medical Education & Research | Method for the treatment of eosinophil-associated diseases by administration of topical anesthetics |
US5633010A (en) | 1992-10-05 | 1997-05-27 | Minnesota Mining And Manufacturing Company | Adhesive compositions, wound dressings and methods |
US5641504A (en) | 1988-06-09 | 1997-06-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolinoleate |
US5641507A (en) | 1993-12-06 | 1997-06-24 | Devillez; Richard L. | Delivery system for dermatological and cosmetic ingredients |
US5643187A (en) | 1992-01-17 | 1997-07-01 | Coloplast A/S | Dressing |
US5645062A (en) | 1993-02-15 | 1997-07-08 | Anderson; John Mccune | Biomedical electrode device |
US5645855A (en) | 1996-03-13 | 1997-07-08 | Ridge Scientific Enterprises, Inc. | Adhesive compositions including polyvinylpyrrolidone acrylic acid polymers, and polyamines |
US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5660178A (en) | 1992-12-01 | 1997-08-26 | Minnesota Mining And Manufacturing Company | Hydrophilic pressure sensitive adhesives |
US5663010A (en) | 1993-11-30 | 1997-09-02 | Olimpio Stocchiero | Device to exhaust the fumes produced inside accumulator batteries |
US5674561A (en) | 1994-01-28 | 1997-10-07 | Minnesota Mining And Manufacturing Company | Polymerized microemulsion pressure sensitive adhesive compositions and methods of preparing and using same |
US5700478A (en) | 1993-08-19 | 1997-12-23 | Cygnus, Inc. | Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity |
US5702721A (en) | 1989-04-01 | 1997-12-30 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system exhibiting an increased active substance flow and process for the production thereof |
JPH1017448A (en) | 1996-06-28 | 1998-01-20 | Lion Corp | Plaster for oral cavity |
US5718886A (en) | 1996-03-11 | 1998-02-17 | Laclede Professional Products, Inc. | Stabilized anhydrous tooth whitening gel |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5718187A (en) | 1992-12-15 | 1998-02-17 | The Gsi Group, Inc. | Poultry feeder |
US5723145A (en) | 1993-09-30 | 1998-03-03 | Takiron Co., Ltd. | Transdermal absorption preparation |
US5726250A (en) | 1994-07-11 | 1998-03-10 | Adhesives Research, Inc. | Covalently crosslinked water-absorbent graft copolymer |
US5725876A (en) | 1996-05-17 | 1998-03-10 | Noven Pharmaceuticals Inc., | Compositions and methods for using low-swell clays in nicotine containing dermal compositions |
US5730999A (en) | 1993-03-27 | 1998-03-24 | Roehm Gmbh Chemische Fabrik | Dermal therapeutic system made of a meltable poly (meth) acrylate |
US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
WO1998020862A1 (en) | 1996-11-11 | 1998-05-22 | Lts Lohmann Therapie-Systeme Gmbh | Immediate wettability water soluble film or water soluble layer for oral application |
US5762956A (en) | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
US5770220A (en) | 1993-12-04 | 1998-06-23 | Lts Lohmann Therapie Systeme Gmbh | Active substance-containing patch |
WO1998026763A1 (en) | 1996-12-16 | 1998-06-25 | Lts Lohmann Therapie-Systeme Gmbh | Active substance carrier for releasing apomorphine into the buccal cavity |
US5773490A (en) | 1993-06-24 | 1998-06-30 | Takiron Co., Ltd. | Pressure sensitive adhesive for transdermal absorption formulations |
US5780050A (en) | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
US5785976A (en) | 1993-03-05 | 1998-07-28 | Pharmacia & Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
US5785527A (en) | 1997-01-10 | 1998-07-28 | Ultradent Products, Inc. | Stable light or heat activated dental bleaching compositions |
US5788983A (en) | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
WO1998037870A1 (en) | 1997-02-28 | 1998-09-03 | Cygnus, Inc. | Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents |
US5804611A (en) | 1995-09-22 | 1998-09-08 | Kansai Paint Co., Ltd. | Composition used for hydrophilization and method for hydrophilization using said composition |
US5827525A (en) | 1995-09-12 | 1998-10-27 | Bristol-Myers Squibb Company | Buccal delivery system for therapeutic agents |
US5827213A (en) | 1995-10-19 | 1998-10-27 | Ole R. Jensen | Heel and elbow dressing |
US5830932A (en) | 1991-08-20 | 1998-11-03 | Bioderm, Inc. | External incontinence device and vapor-absorptive adhesive compositions |
US5837713A (en) | 1997-02-26 | 1998-11-17 | Mayo Foundation For Medical Education And Research | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids |
US5843472A (en) | 1997-02-28 | 1998-12-01 | Cygnus, Inc. | Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use |
US5846558A (en) | 1996-03-19 | 1998-12-08 | Minnesota Mining And Manufacturing Company | Ionically conductive adhesives prepared from zwitterionic materials and medical devices using such adhesives |
WO1998055044A1 (en) | 1997-06-06 | 1998-12-10 | The Procter & Gamble Company | A delivery system for a tooth whitener using a strip of material having low flexural stiffness |
US5851549A (en) | 1994-05-25 | 1998-12-22 | Becton Dickinson And Company | Patch, with system and apparatus for manufacture |
EP0511782B1 (en) | 1991-04-23 | 1998-12-23 | Perio Products Limited | Polymer composition for tooth bleaching and other dental uses thereof |
US5853755A (en) | 1993-07-28 | 1998-12-29 | Pharmaderm Laboratories Ltd. | Biphasic multilamellar lipid vesicles |
US5858332A (en) | 1997-01-10 | 1999-01-12 | Ultradent Products, Inc. | Dental bleaching compositions with high concentrations of hydrogen peroxide |
US5858410A (en) | 1994-11-11 | 1999-01-12 | Medac Gesellschaft Fur Klinische Spezialpraparate | Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution |
US5863662A (en) | 1996-05-14 | 1999-01-26 | Isp Investments Inc. | Terpolymer for ink jet recording |
WO1999007940A1 (en) | 1997-08-05 | 1999-02-18 | B-Mac, Besloten Vennootschap Met Beperkte Aansprakelijkheid | Vibrating device for processing a floor layer |
US5876746A (en) | 1995-06-07 | 1999-03-02 | Cygnus, Inc. | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
US5879691A (en) | 1997-06-06 | 1999-03-09 | The Procter & Gamble Company | Delivery system for a tooth whitener using a strip of material having low flexural stiffness |
WO1999011728A1 (en) | 1997-08-29 | 1999-03-11 | Avery Dennison Corporation | Biological fluid absorbing pressure sensitive adhesives |
EP0838225A3 (en) | 1996-10-25 | 1999-03-24 | Hiji, Yasutake | Aqueous local anesthetic solution |
US5894017A (en) | 1997-06-06 | 1999-04-13 | The Procter & Gamble Company | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
WO1999017738A1 (en) | 1997-10-03 | 1999-04-15 | Lavipharm Laboratories, Inc. | A prolamine-plant polar lipid composition, its method of preparation and applications thereof |
US5900249A (en) | 1998-02-09 | 1999-05-04 | Smith; David J. | Multicomponent pain relief topical medication |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US5912271A (en) | 1994-07-12 | 1999-06-15 | Astra Ab | Pharmaceutical preparation for pain management |
US5911980A (en) | 1996-06-27 | 1999-06-15 | Macrochem Corporation | Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin |
US5916587A (en) | 1992-12-31 | 1999-06-29 | Sunkyong Industries Co., Ltd. | Transdermal delivery matrix for piroxicam |
US5942543A (en) | 1994-07-15 | 1999-08-24 | Ernst; Amy A. | Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use |
US5945457A (en) | 1997-10-01 | 1999-08-31 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science | Process for preparing biologically compatible polymers and their use in medical devices |
US5945032A (en) | 1996-09-30 | 1999-08-31 | Basf Aktiengesellschaft | Polymer/hydrogen peroxide complexes |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
US5948416A (en) | 1995-06-29 | 1999-09-07 | The Procter & Gamble Company | Stable topical compositions |
WO1999044678A1 (en) | 1998-03-06 | 1999-09-10 | Spectrx, Inc. | Apparatus for electroporation through microporated tissue |
WO1999047128A1 (en) | 1998-03-19 | 1999-09-23 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
US5958984A (en) | 1996-10-10 | 1999-09-28 | Devillez; Richard L. | Method and composition for skin treatment |
US5958446A (en) | 1988-03-04 | 1999-09-28 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5958379A (en) | 1994-09-30 | 1999-09-28 | Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh | Pharmaceutical composition |
US5962011A (en) | 1993-12-06 | 1999-10-05 | Schering-Plough Healthcare Products, Inc. | Device for delivery of dermatological ingredients |
WO1999054422A1 (en) | 1998-04-21 | 1999-10-28 | Coloplast A/S | A pressure sensitive adhesive composition |
US5976565A (en) | 1996-06-20 | 1999-11-02 | Lavipharm Laboratories, Inc. | Device for topical treatment of acne and its method of manufacture |
WO1999055312A2 (en) | 1998-04-29 | 1999-11-04 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
US5985990A (en) | 1995-12-29 | 1999-11-16 | 3M Innovative Properties Company | Use of pendant free-radically polymerizable moieties with polar polymers to prepare hydrophilic pressure sensitive adhesive compositions |
US5985311A (en) | 1995-07-22 | 1999-11-16 | Labtec Gesellschaft Fuer Techologische Forschung Und Entwicklung Mbh | Transdermal hormone patch |
US5985860A (en) | 1992-06-03 | 1999-11-16 | Toppo; Frank | System for transdermal delivery of pain relieving substances |
US5989569A (en) | 1997-06-06 | 1999-11-23 | The Procter & Gamble Company | Delivery system for a tooth whitener using a permanently deformable strip of material |
US5990179A (en) | 1995-04-28 | 1999-11-23 | Alza Corporation | Composition and method of enhancing electrotransport agent delivery |
US5993836A (en) | 1998-04-28 | 1999-11-30 | Castillo; James G. | Topical anesthetic formulation |
US5993849A (en) | 1996-12-20 | 1999-11-30 | Roehm Gmbh Chemische Fabrik | Hydrophilic adhesive and binder for medications |
US5997886A (en) | 1997-11-05 | 1999-12-07 | The Procter & Gamble Company | Personal care compositions |
US6004566A (en) | 1992-03-26 | 1999-12-21 | Pharmos Corp. | Topical and transdermal delivery system utilizing submicron oil spheres |
US6004578A (en) | 1996-10-24 | 1999-12-21 | Alza Corporation | Permeation enhances for transdermal drug delivery compositions, devices and methods |
US6007837A (en) | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture |
US6045811A (en) | 1997-06-06 | 2000-04-04 | The Procter & Gamble Company | Delivery system for an oral care substance using a permanently deformable strip of material |
WO2000018365A2 (en) | 1998-09-25 | 2000-04-06 | Warner-Lambert Company | Fast dissolving orally consumable films |
US6051609A (en) | 1997-09-09 | 2000-04-18 | Tristrata Technology, Inc. | Additives enhancing the effect of therapeutic agents |
US6063399A (en) | 1996-12-20 | 2000-05-16 | Roehm Gmbh Chemische Fabrik | Adhesive binders for dermal or transdermal therapy systems |
US6068650A (en) | 1997-08-01 | 2000-05-30 | Gentronics Inc. | Method of Selectively applying needle array configurations |
US6072100A (en) | 1998-01-28 | 2000-06-06 | Johnson & Johnson Consumer Products, Inc. | Extrudable compositions for topical or transdermal drug delivery |
US6075626A (en) | 1997-06-25 | 2000-06-13 | Denso Corporation | Hologram |
US6083421A (en) | 1996-01-19 | 2000-07-04 | Huang; Lizi | Film coating composition for whitening teeth |
US6093328A (en) | 1994-12-08 | 2000-07-25 | Santina; Peter F. | Method for removing toxic substances in water |
US6096328A (en) | 1997-06-06 | 2000-08-01 | The Procter & Gamble Company | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
WO2000061120A1 (en) | 1999-04-13 | 2000-10-19 | Hisamitsu Pharmaceutical Co., Inc. | Preparations for percutaneous absorption |
US6135126A (en) | 1997-08-07 | 2000-10-24 | Microlin, L.C. | Brush that delivers beneficial agents |
US6142939A (en) | 1993-11-15 | 2000-11-07 | Spectrx, Inc. | Microporation of human skin for drug delivery and monitoring applications |
US6146654A (en) | 1996-06-10 | 2000-11-14 | Alcare Co., Ltd. | Adhesive medical composition with sustained medicament releasbility and process for preparing same |
US6162456A (en) | 1992-09-24 | 2000-12-19 | Ortho-Mcneil Pharmaceutical, Inc. | Adhesive transdermal drug delivery matrix of a physical blend of hydrophilic and hydrophobic polymers |
US6165499A (en) | 1996-03-25 | 2000-12-26 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic system with small application-area thickness and great flexibility, and production process |
WO2001001958A1 (en) | 1999-07-02 | 2001-01-11 | The Procter & Gamble Company | Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip |
WO2001007018A1 (en) | 1999-07-27 | 2001-02-01 | Hisamitsu Pharmaceutical Co., Inc. | Patches for external use |
US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
US6197331B1 (en) | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
US6201164B1 (en) | 1996-07-11 | 2001-03-13 | Coloplast A/S | Hydrocolloid wound gel |
WO2000069421A3 (en) | 1999-05-18 | 2001-03-22 | Sanol Arznei Schwarz Gmbh | Transdermal therapeutic system (tts) containing tolterodine |
US6212671B1 (en) | 1997-10-20 | 2001-04-03 | Mitsubishi Electric System Lsi Design Corporation | Mask pattern data producing apparatus, mask pattern data producing method and semiconductor integrated circuit device |
US6221341B1 (en) | 1997-11-19 | 2001-04-24 | Oraceutical Llc | Tooth whitening compositions |
US6231885B1 (en) | 1997-09-17 | 2001-05-15 | Permatec Technologie Ag | Composition for controlled and sustained transdermal administration |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20010006677A1 (en) | 1996-10-29 | 2001-07-05 | Mcginity James W. | Effervescence polymeric film drug delivery system |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US6270792B1 (en) | 1998-09-18 | 2001-08-07 | Laboratories D'hygiene Et De Dietique | Sterile nonstick compress |
JP2001213768A (en) | 2000-02-01 | 2001-08-07 | Okayama Taiho Pharmaceutical Co Ltd | Poultice |
US6275728B1 (en) | 1998-12-22 | 2001-08-14 | Alza Corporation | Thin polymer film drug reservoirs |
WO2001068045A1 (en) | 2000-03-17 | 2001-09-20 | Lg Household & Health Care Ltd | Patches for teeth whitening |
US6306370B1 (en) | 1997-05-30 | 2001-10-23 | Ultradent Products, Inc. | Compositions and methods for whitening and desensitizing teeth |
US6312666B1 (en) | 1998-11-12 | 2001-11-06 | 3M Innovative Properties Company | Methods of whitening teeth |
US6316022B1 (en) | 1995-06-07 | 2001-11-13 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
WO2001087276A1 (en) | 2000-05-16 | 2001-11-22 | Samyang Corporation | Hydrogel composition for transdermal drug delivery |
US6322774B1 (en) | 1999-12-20 | 2001-11-27 | Ultradent Products, Inc. | Dental bleaching compositions containing sucralose |
US20010046471A1 (en) | 2000-05-09 | 2001-11-29 | Marek Przemyslaw A. | Infrared thermograpy and methods of use |
US6329472B1 (en) | 1998-11-18 | 2001-12-11 | Basf Aktiengesellschaft | Water-soluble or water-dispersible graft copolymers based on a polyvinyllactam, their preparation and use |
WO2001026637A3 (en) | 1999-10-13 | 2001-12-13 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid |
US20020004190A1 (en) | 2000-05-26 | 2002-01-10 | Adam Diasti | Method for whitening teeth |
US20020009420A1 (en) | 2000-04-11 | 2002-01-24 | Mclaughlin Gerald | Composition and method for whitening teeth |
JP2002029949A (en) | 2000-07-19 | 2002-01-29 | Lion Corp | Composition for oral cavity |
US6368576B1 (en) | 1998-11-12 | 2002-04-09 | Ultradent Products, Inc. | Methods for bleaching, opacifying and desensitizing teeth |
WO2002004570A3 (en) | 2000-07-07 | 2002-04-18 | Av Topchiev Inst Petrochemical | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
US20020048602A1 (en) | 2000-06-22 | 2002-04-25 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
JP2002145746A (en) | 2000-11-02 | 2002-05-22 | Haruyuki Kawahara | Tooth bleaching agent |
WO2002043657A2 (en) | 2000-11-30 | 2002-06-06 | Wm. Wrigley Jr. Company | Improved pullulan free edible film compositions and methods of making the same |
KR20020045224A (en) | 2000-12-08 | 2002-06-19 | 성재갑 | Peroxide Stabilized Patches for Teeth Whitening |
US20020076487A1 (en) | 2000-03-06 | 2002-06-20 | Bohdan Zajac | Method for protecting paint on an article, a composition useful therefor, and a method for making the composition |
US6419906B1 (en) | 2001-03-12 | 2002-07-16 | Colgate Palmolive Company | Strip for whitening tooth surfaces |
US6419905B1 (en) | 1998-03-20 | 2002-07-16 | Biocosmetics, S.L. | Tooth whitening composition |
WO2002000182A3 (en) | 2000-06-28 | 2002-07-25 | Procter & Gamble | Structures and compositions increasing the stability of peroxide actives |
US20020106335A1 (en) | 2000-09-20 | 2002-08-08 | Orlowski Jan A. | Two-part composition for high efficacy teeth whitening comprising a mixture of peroxides and/or percarbonates of metals |
US6451777B1 (en) | 1998-07-17 | 2002-09-17 | The University Of Texas Southwestern Medical Center | Method for regulating hair growth |
US6451240B1 (en) | 1999-06-09 | 2002-09-17 | The Procter & Gamble Company | Method of manufacturing an intracutaneous microneedle array |
US6461636B1 (en) | 1998-05-15 | 2002-10-08 | Schwarz Pharma Ag | Transdermal therapeutic system containing pergolide |
WO2002087645A1 (en) | 2001-05-01 | 2002-11-07 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions |
US20020197284A1 (en) | 1999-12-16 | 2002-12-26 | Luo Eric C. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
WO2003000216A1 (en) | 2001-06-23 | 2003-01-03 | Lg Household & Health Care Ltd. | Multiple-layered patches for teeth whitening |
KR20030000299A (en) | 2001-06-23 | 2003-01-06 | 주식회사 엘지생활건강 | Semi-transparent patches for teeth whitening |
KR20030000528A (en) | 2001-06-26 | 2003-01-06 | 주식회사 엘지생활건강 | Patches for teeth whitening |
WO2002087642A3 (en) | 2001-05-01 | 2003-01-09 | Av Topchiev Inst Petrochemical | Two-phase, water-absorbent bioadhesive composition |
KR20030003973A (en) | 2001-07-04 | 2003-01-14 | 주식회사 엘지생활건강 | Flexible patches for teeth whitening |
KR20030003969A (en) | 2001-07-04 | 2003-01-14 | 주식회사 엘지생활건강 | Manufacturing process of patches for teeth whitening |
WO2003011259A1 (en) | 2001-07-30 | 2003-02-13 | Wm. Wrigley Jr. Company | Improved edible film formulations containing maltodextrin |
US20030035841A1 (en) | 2001-07-30 | 2003-02-20 | Dzija Michael R. | Edible film formulations containing maltodextrin |
US20030055190A1 (en) | 1998-09-22 | 2003-03-20 | Hsing-Yeh Parker | Acrylic polymer compositions with crystalline side chains and processes for their preparation |
WO2002089849B1 (en) | 2001-05-07 | 2003-04-03 | Corium Int | Compositions and delivery systems for administration of a local anesthetic agent |
US20030068376A1 (en) | 2001-04-20 | 2003-04-10 | Lavipharm Laboratories Inc. | Intraoral delivery of nicotine for smoking cessation |
US6562363B1 (en) | 1997-09-26 | 2003-05-13 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US20030100654A1 (en) | 2001-06-29 | 2003-05-29 | Theary Chheang | Devices, compositions, and methods incorporating adhesives whose performance is enhanced by organophilic clay constituents |
US20030101507A1 (en) | 2001-12-03 | 2003-06-05 | Cleary Stephen P. | Goggle with side arm for wearing with a helmet |
US20030104041A1 (en) | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
US20030103427A1 (en) | 1998-05-09 | 2003-06-05 | Lg Electronics Inc. | Method for forming an information recording medium having information on spare area, and method and apparatus for recording/ reproducing data to/ from the medium |
US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
US6591124B2 (en) | 2001-05-11 | 2003-07-08 | The Procter & Gamble Company | Portable interstitial fluid monitoring system |
US6602912B2 (en) | 2000-06-30 | 2003-08-05 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
US20030152528A1 (en) | 2001-05-01 | 2003-08-14 | Parminder Singh | Hydrogel compositions for tooth whitening |
US20030152615A1 (en) | 2001-06-18 | 2003-08-14 | Noven Pharmaceuticals, Inc. | Enhanced drug delivery in transdermal systems |
US6611706B2 (en) | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
US20030180229A1 (en) | 2002-03-21 | 2003-09-25 | Kosti Carl M. | Bleach stable toothpaste |
US6638528B1 (en) | 2000-01-20 | 2003-10-28 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
WO2003089046A1 (en) | 2002-04-16 | 2003-10-30 | Cyto Pulse Sciences, Inc. | Method of treating biological materials with translating electrical fields and electrode polarity reversal |
US20030225356A1 (en) | 2002-05-24 | 2003-12-04 | Kulichikhin Valery G. | Composition for cushions, wound dressings and other skin-contacting products |
WO2003101357A1 (en) | 2002-05-31 | 2003-12-11 | University Of Mississippi | Transmucosal delivery of cannabinoids |
US6667410B2 (en) | 2000-09-18 | 2003-12-23 | Board Of Regents, The University Of Texas System | Conversion of α,β-unsaturated ketones and α,β-unsaturated esters into α-hydroxy ketones and α-hydroxy esters using Mn(III) catalyst, phenylsilane and dioxygen |
US20030235549A1 (en) | 2001-05-01 | 2003-12-25 | Parminder Singh | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US20040005277A1 (en) | 2002-07-02 | 2004-01-08 | Willison Michael P. | Device and method for delivering an oral care agent |
US6689344B2 (en) | 2000-03-17 | 2004-02-10 | Lg Household & Healthcare Ltd. | Patches for teeth whitening |
US6696459B1 (en) | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
US6708060B1 (en) | 1998-11-09 | 2004-03-16 | Transpharma Ltd. | Handheld apparatus and method for transdermal drug delivery and analyte extraction |
US20040053901A1 (en) | 1999-11-24 | 2004-03-18 | Te-Yen Chien | Transdermal hormone delivery system: compositions and methods |
US6711435B2 (en) | 1998-11-09 | 2004-03-23 | Transpharma Ltd. | Transdermal drug delivery and analyte extraction |
WO2004045569A1 (en) | 2002-11-21 | 2004-06-03 | Lg Household & Health Care Ltd. | Dry type patches safe for gum |
US20040105834A1 (en) | 2001-05-01 | 2004-06-03 | Corium International | Hydrogel compositions with an erodible backing member |
US6750291B2 (en) | 2002-04-12 | 2004-06-15 | Pacific Corporation | Film-forming agent for drug delivery and preparation for percutaneous administration containing the same |
US20040136927A1 (en) | 2000-03-17 | 2004-07-15 | Ji-Young Kim | Apparatus and method for whitening teeth |
WO2004054638A3 (en) | 2002-12-13 | 2004-08-12 | Corium Int Inc | Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
US6805874B1 (en) | 2002-12-03 | 2004-10-19 | Permamed Ag | Method and skin cleansing compositions for dermatological basic treatment |
US20040219111A1 (en) | 2000-03-17 | 2004-11-04 | Ji-Young Kim | Method and device for teeth whitening using a dry type adhesive |
US20040258723A1 (en) | 2001-05-01 | 2004-12-23 | Parminder Singh | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
WO2005074894A1 (en) | 2004-01-30 | 2005-08-18 | Corium International | Rapidly dissolving film for delivery of an active agent |
US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US20050228113A1 (en) | 2002-08-08 | 2005-10-13 | Basf Coatings Aktiengesellschaft | Coating materials and the use thereof for the production of weldable coatings |
US6962691B1 (en) | 1999-05-20 | 2005-11-08 | U & I Pharmaceuticals Ltd. | Topical spray compositions |
US20050256223A1 (en) | 2004-05-17 | 2005-11-17 | Kolb Brant U | Dental compositions containing nanozirconia fillers |
US20060034905A1 (en) | 2004-08-05 | 2006-02-16 | Parminder Singh | Adhesive composition |
WO2004093786A3 (en) | 2003-04-16 | 2006-03-23 | Corium Int | Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith |
US20060110434A1 (en) | 2004-11-22 | 2006-05-25 | Toshiro Yamaguchi | Drug-containing patch |
US7078359B2 (en) | 2000-12-22 | 2006-07-18 | Aspen Aerogels, Inc. | Aerogel composite with fibrous batting |
US20060171906A1 (en) | 2004-12-21 | 2006-08-03 | Corium International, Inc. | Sustained release tooth whitening formulations and systems |
US20060168905A1 (en) | 2002-11-05 | 2006-08-03 | Wilfried Blanc | Light-converting material comprising a barium magenesium silicate as additive |
US20060182788A1 (en) | 2005-01-27 | 2006-08-17 | Parminder Singh | Hydrophilic biocompatible adhesive formulations and uses |
US7112713B2 (en) | 2003-03-12 | 2006-09-26 | Gelsus Research And Consulting, Inc. | Dressing based on the Teorell-Meyer gradient |
US7122199B2 (en) | 1997-06-06 | 2006-10-17 | The Procter & Gamble Company | Methods for whitening teeth |
WO2006124639A1 (en) | 2005-05-11 | 2006-11-23 | Corium International, Inc. | Permeabilization of biological membranes |
WO2007119656A1 (en) | 2006-04-11 | 2007-10-25 | Nichiban Co., Ltd. | Tamsulosin-containing percutaneous absorption type preparation |
CA2520986C (en) | 1998-09-25 | 2007-11-13 | Warner-Lambert Company | Physiological compatible film |
US7323161B2 (en) | 2003-04-30 | 2008-01-29 | Icure Pharmaceutical Corp. | Patch for tooth whitening |
WO2010083035A2 (en) | 2009-01-14 | 2010-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1459215A1 (en) | 1986-12-30 | 1995-11-20 | Всесоюзный Научно-Исследовательский Институт Биотехнологии | Composition of polymeric diffusion matrix for transdermal administration of drugs |
-
2005
- 2005-06-10 US US11/150,811 patent/USRE44145E1/en not_active Expired - Lifetime
-
2013
- 2013-02-06 US US13/761,118 patent/USRE45666E1/en not_active Expired - Lifetime
Patent Citations (396)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2561071A (en) | 1949-09-21 | 1951-07-17 | Prisk Howard Conley | Holder for subcutaneous administration of medicaments |
US2579403A (en) | 1950-06-01 | 1951-12-18 | Slomowitz Julius | Medical bandage |
US3150977A (en) | 1959-12-23 | 1964-09-29 | Gevaert Photo Prod Nv | Light-sensitive photographic materials |
GB1108837A (en) | 1965-11-30 | 1968-04-03 | Astra Pharma Prod | Improvements in material for causing local anaesthesia |
US3689439A (en) | 1968-06-12 | 1972-09-05 | Gaf Corp | Process for preparing a crosslinked porous polyvinyl pyrrolidone granule |
US3721657A (en) | 1969-07-28 | 1973-03-20 | M Seiderman | Hydrophilic gel polymers of vinylpyrrolidine and hydroxyalkyl methacrylate |
US3749755A (en) | 1969-12-22 | 1973-07-31 | Basf Ag | Thermoplastic molding compositions of high impact resistance |
US3852228A (en) | 1971-01-07 | 1974-12-03 | D Brothers | Thixotropic coating composition |
US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
US3957605A (en) | 1973-09-10 | 1976-05-18 | Union Carbide Corporation | Process for radiation cocrosslinking water soluble polymers and products thereof |
US3993551A (en) | 1973-09-10 | 1976-11-23 | Union Carbide Corporation | Process for cocrosslinking water soluble polymers and products thereof |
US4091090A (en) | 1974-07-08 | 1978-05-23 | Johnson & Johnson | Potentiated anesthetics |
US4093673A (en) | 1974-11-14 | 1978-06-06 | Ppg Industries, Inc. | Coating compositions composed of hydroxyfunctional polymers or copolymers and alkoxysilanes |
US4160020A (en) | 1975-11-24 | 1979-07-03 | Alza Corporation | Therapeutic device for osmotically dosing at controlled rate |
US4231369A (en) | 1977-05-24 | 1980-11-04 | Coloplast International A/S | Sealing material for ostomy devices |
US4562060A (en) | 1977-12-01 | 1985-12-31 | Astra Lakemedel Aktiebolag | Local anesthetic mixture for topical application, process for its preparation, as well as method for obtaining local anesthesia |
US4529601A (en) | 1977-12-01 | 1985-07-16 | Astra Lakemedel Aktiebolag | Local anesthetic mixture for topical application and method for obtaining local anesthesia |
US4277580A (en) | 1978-05-22 | 1981-07-07 | Texaco Inc. | Terpolymer of N-vinyl pyrrolidone in alkoxylated form |
US4492685A (en) | 1979-08-14 | 1985-01-08 | Key Pharmaceuticals, Inc. | Protective skin matrix |
US4552751A (en) | 1980-10-17 | 1985-11-12 | Ono Pharmaceutical Co., Ltd. | Long-lasting multi-layered film preparation |
US4325851A (en) | 1980-10-24 | 1982-04-20 | Herman Colon | Water-activatable hot-melt adhesives |
US4346709A (en) | 1980-11-10 | 1982-08-31 | Alza Corporation | Drug delivery devices comprising erodible polymer and erosion rate modifier |
US4367732A (en) | 1980-12-05 | 1983-01-11 | Coloplast A/S | Skin barrier |
US4750482A (en) | 1982-02-25 | 1988-06-14 | Pfizer Inc. | Hydrophilic, elastomeric, pressure-sensitive adhesive |
US4699146A (en) | 1982-02-25 | 1987-10-13 | Valleylab, Inc. | Hydrophilic, elastomeric, pressure-sensitive adhesive |
JPS58162681U (en) | 1982-04-22 | 1983-10-29 | ソニー株式会社 | Electrical equipment operating device |
US4871536A (en) | 1982-06-17 | 1989-10-03 | L'oreal | Composition based on cationic polymers, anionic polymers and waxes for use in cosmetics |
JPH0366612B2 (en) | 1982-06-29 | 1991-10-18 | Shimadzu Corp | |
US4587289A (en) | 1982-09-27 | 1986-05-06 | Ahmet Comert | Adhesive thermoplastic compositions |
JPS59196817A (en) | 1983-04-21 | 1984-11-08 | Sekisui Chem Co Ltd | Application drug |
US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US5224928A (en) | 1983-08-18 | 1993-07-06 | Drug Delivery Systems Inc. | Mounting system for transdermal drug applicator |
US5593686A (en) | 1984-03-01 | 1997-01-14 | Sandoz Ltd. | Pharmaceutical compositions |
US4904247A (en) | 1984-08-31 | 1990-02-27 | Kendall Company | Pressure-sensitive hydrophilic laminate structures for use in wound dressing, transdermal and topical drug delivery |
US4624665A (en) | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
EP0184470B1 (en) | 1984-12-07 | 1991-04-17 | Medtronic, Inc. | Hydrophilic, pressure sensitive biomedical adhesive composition |
US4593053A (en) | 1984-12-07 | 1986-06-03 | Medtronic, Inc. | Hydrophilic pressure sensitive biomedical adhesive composition |
DE8509793U1 (en) | 1985-04-02 | 1985-05-15 | Allpack Industrielle Lohnverpackung GmbH & Co KG, 7050 Waiblingen | Pharmaco adhesive plaster |
US4771105A (en) | 1986-02-05 | 1988-09-13 | Sekisui Kaseihin Kogyo Kabushiki Kaisha | Water-absorbent resin and process for producing the same |
US4743249A (en) | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
US4873299A (en) | 1986-03-21 | 1989-10-10 | Basf Aktiengesellschaft | Batchwise preparation of crosslinked, finely divided polymers |
US5141750A (en) | 1986-06-13 | 1992-08-25 | Alza Corporation | Delayed onset transdermal delivery device |
US4713243A (en) | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
US5342623A (en) | 1986-09-12 | 1994-08-30 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US5462745A (en) | 1986-09-12 | 1995-10-31 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US4867748A (en) | 1986-10-17 | 1989-09-19 | Coloplast A/S | Dressing with hydrocolloid |
US4863970A (en) | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US4945084A (en) | 1987-07-08 | 1990-07-31 | Norman Oksman | Method and composition for topically treating anorectal or other dermal wounds |
US5196405A (en) | 1987-07-08 | 1993-03-23 | Norman H. Oskman | Compositions and methods of treating hemorrhoids and wounds |
EP0303445A1 (en) | 1987-08-13 | 1989-02-15 | Walton S.A. | Clebopride transdermal patch |
US4877628A (en) | 1987-09-03 | 1989-10-31 | International Flavors & Fragrances Inc. | Process for preparing a coated food product |
US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
WO1989003859A1 (en) | 1987-10-23 | 1989-05-05 | Vsesojuzny Nauchno-Issledovatelsky Institut Biotek | Composition of polymer diffusion matrix for transdermally introducing pharmaceutical substances |
US4983395A (en) | 1987-11-12 | 1991-01-08 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4849224A (en) | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4863738A (en) | 1987-11-23 | 1989-09-05 | Alza Corporation | Skin permeation enhancer compositions using glycerol monooleate |
US5254346A (en) | 1988-02-23 | 1993-10-19 | Tucker Mark J | Occlusive body for administering a physiologically active substance |
US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5958446A (en) | 1988-03-04 | 1999-09-28 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5300291A (en) | 1988-03-04 | 1994-04-05 | Noven Pharmaceuticals, Inc. | Method and device for the release of drugs to the skin |
US6024976A (en) | 1988-03-04 | 2000-02-15 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5438076A (en) | 1988-05-03 | 1995-08-01 | Perio Products, Ltd. | Liquid polymer composition, and method of use |
US5641504A (en) | 1988-06-09 | 1997-06-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolinoleate |
US5456745A (en) | 1988-08-13 | 1995-10-10 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Flexible, hydrophilic gel film, the process for its production and the use of it |
US5073381A (en) | 1988-08-15 | 1991-12-17 | University Of Akron | Amphiphilic networks |
US5599373A (en) | 1988-09-30 | 1997-02-04 | F.P.S.- Finances Products Services, S.R.L. | Sulfur-based chemical soil-corrective in the form of pellets for agricultural use |
US4927408A (en) | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
US5200190A (en) | 1988-10-11 | 1993-04-06 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Percutaneous pharmaceutical preparation |
EP0364211B1 (en) | 1988-10-11 | 1994-12-21 | Shire Holdings Ltd. | A percutaneous pharmaceutical preparation |
JPH01151524A (en) | 1988-11-10 | 1989-06-14 | Yamanouchi Pharmaceut Co Ltd | 'satotsu-ko' poultice and preparation thereof |
EP0371421B1 (en) | 1988-11-28 | 1994-12-21 | The B.F. Goodrich Company | Crosslinked polyacrylic acid |
US4953053A (en) | 1989-01-31 | 1990-08-28 | Harnischfeger Corporation | Method and apparatus for detecting mechanical overload of a hoist |
JPH06100467B2 (en) | 1989-02-06 | 1994-12-12 | 株式会社シ−エックスア−ル | Proximity sensor |
US5240995A (en) | 1989-02-09 | 1993-08-31 | Alza Corporation | Electrotransport adhesive |
US5344394A (en) | 1989-02-09 | 1994-09-06 | Alza Corporation | Iontophoretic device incorporating an electrotransport adhesive |
US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
US5053227A (en) | 1989-03-22 | 1991-10-01 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
US5702721A (en) | 1989-04-01 | 1997-12-30 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system exhibiting an increased active substance flow and process for the production thereof |
US5788983A (en) | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
US5296512A (en) | 1989-04-26 | 1994-03-22 | Rohm Gmbh Chemische Fabrik | Water-soluble pressure-sensitive skin adhesive, its use, and agents provided with it |
US5133970A (en) | 1989-07-24 | 1992-07-28 | Rohm Gmbh Chemische Fabrik | Water-soluble pressure-sensitive skin-adhesive and use thereof |
US5102662A (en) | 1989-12-08 | 1992-04-07 | Dow Corning Corporation | Insect repellent plastic |
US5270358A (en) | 1989-12-28 | 1993-12-14 | Minnesota Mining And Manufacturing Company | Composite of a disperesed gel in an adhesive matrix |
US5057500A (en) | 1990-02-12 | 1991-10-15 | Dermatologic Research Corporation | Treatment of pruritis with esters and amides |
JPH03247334A (en) | 1990-02-26 | 1991-11-05 | Sumitomo Rubber Ind Ltd | Cold insulant |
JPH03275619A (en) | 1990-03-23 | 1991-12-06 | Nitsusui Seiyaku Kk | External agent composition |
US5125894A (en) | 1990-03-30 | 1992-06-30 | Alza Corporation | Method and apparatus for controlled environment electrotransport |
US5173302A (en) | 1990-09-28 | 1992-12-22 | Medtronic, Inc. | Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs |
US5376377A (en) | 1990-10-29 | 1994-12-27 | Alza Corporation | Transdermal contraceptive formulations, methods and devices |
US5326685A (en) | 1991-02-13 | 1994-07-05 | Gaglio Thomas J | Viscous fluid dispensing apparatus |
JPH04266818A (en) | 1991-02-21 | 1992-09-22 | Sekisui Chem Co Ltd | Tacky agent for medical application |
US5332576A (en) | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5446070A (en) | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5234957A (en) | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
EP0511782B1 (en) | 1991-04-23 | 1998-12-23 | Perio Products Limited | Polymer composition for tooth bleaching and other dental uses thereof |
EP0516026A1 (en) | 1991-05-28 | 1992-12-02 | Takeda Chemical Industries, Ltd. | Hydrogel and method of producing same |
US5232702A (en) | 1991-07-22 | 1993-08-03 | Dow Corning Corporation | Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices |
WO1993002717A1 (en) | 1991-08-09 | 1993-02-18 | Smith & Nephew Plc | Adhesive products |
US5830932A (en) | 1991-08-20 | 1998-11-03 | Bioderm, Inc. | External incontinence device and vapor-absorptive adhesive compositions |
US5234690A (en) | 1991-08-23 | 1993-08-10 | Cygnus Therapeutic Systems | Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset |
US5310563A (en) | 1991-10-25 | 1994-05-10 | Colgate-Palmolive Company | Dental material and method for applying preventative and therapeutic agents |
US5362420A (en) | 1991-11-15 | 1994-11-08 | Minnesota Mining And Manufacturing Company | Low impedance pressure sensitive adhesive composition and biomedical electrodes using same |
US5338490A (en) | 1991-11-15 | 1994-08-16 | Minnesota Mining And Manufacturing Company | Two-phase composites of ionically-conductive pressure-sensitive adhesive, biomedical electrodes using the composites, and methods of preparing the composite and the biomedical electrodes |
US5276079A (en) | 1991-11-15 | 1994-01-04 | Minnesota Mining And Manufacturing Company | Pressure-sensitive poly(n-vinyl lactam) adhesive composition and method for producing and using same |
EP0545594B1 (en) | 1991-11-22 | 1996-05-01 | Colgate-Palmolive Company | Oral composition having improved tooth whitening effect |
US5643187A (en) | 1992-01-17 | 1997-07-01 | Coloplast A/S | Dressing |
US5183901A (en) | 1992-01-24 | 1993-02-02 | Isp Investments Inc. | Urea-hydrogen peroxide-polyvinylpyrrolidone |
US5206385A (en) | 1992-01-24 | 1993-04-27 | Isp Investments Inc. | Urea-hydrogen peroxide-polyvinylpyrrolidone process |
US5322689A (en) | 1992-03-10 | 1994-06-21 | The Procter & Gamble Company | Topical aromatic releasing compositions |
US6004566A (en) | 1992-03-26 | 1999-12-21 | Pharmos Corp. | Topical and transdermal delivery system utilizing submicron oil spheres |
US5508024A (en) | 1992-05-22 | 1996-04-16 | International Research And Development Corp. | Topical antiperspirant composition consisting essentially of non-toxic water-insoluble occlusive film-forming antiperspirant polymer |
US5985860A (en) | 1992-06-03 | 1999-11-16 | Toppo; Frank | System for transdermal delivery of pain relieving substances |
DE4219368C2 (en) | 1992-06-12 | 1994-07-28 | Lohmann Gmbh & Co Kg | Electrically conductive transparent pressure sensitive adhesive films, process for their production and use for the production of biomedical electrodes |
US5614178A (en) | 1992-07-28 | 1997-03-25 | The Procter & Gamble Company | Compositions for topical delivery of drugs comprising a mixture of high and low HLB surfactants and alkoxylated ether |
EP0581581A3 (en) | 1992-07-29 | 1996-01-17 | Johnson & Johnson Consumer | Bioadhesive treatment compositions and methods of use |
WO1994005340A1 (en) | 1992-08-27 | 1994-03-17 | Coloplast A/S | A dressing for dosing one or more medicaments |
US6153215A (en) | 1992-08-27 | 2000-11-28 | Colorplast A/S | Dressing for dosing one or more medicaments |
US6162456A (en) | 1992-09-24 | 2000-12-19 | Ortho-Mcneil Pharmaceutical, Inc. | Adhesive transdermal drug delivery matrix of a physical blend of hydrophilic and hydrophobic polymers |
US5633010A (en) | 1992-10-05 | 1997-05-27 | Minnesota Mining And Manufacturing Company | Adhesive compositions, wound dressings and methods |
US5462743A (en) | 1992-10-30 | 1995-10-31 | Medipro Sciences Limited | Substance transfer system for topical application |
US5575654A (en) | 1992-11-24 | 1996-11-19 | Fontenot; Mark G. | Apparatus and method for lightening teeth |
EP0672094B1 (en) | 1992-12-01 | 1997-09-24 | Minnesota Mining And Manufacturing Company | Hydrophilic polyoxyethylene pressure sensitive adhesives |
US5660178A (en) | 1992-12-01 | 1997-08-26 | Minnesota Mining And Manufacturing Company | Hydrophilic pressure sensitive adhesives |
US5718187A (en) | 1992-12-15 | 1998-02-17 | The Gsi Group, Inc. | Poultry feeder |
US5916587A (en) | 1992-12-31 | 1999-06-29 | Sunkyong Industries Co., Ltd. | Transdermal delivery matrix for piroxicam |
US5631267A (en) | 1993-02-02 | 1997-05-20 | Mayo Foundation For Medical Education & Research | Method for the treatment of eosinophil-associated diseases by administration of topical anesthetics |
US5645062A (en) | 1993-02-15 | 1997-07-08 | Anderson; John Mccune | Biomedical electrode device |
US5785976A (en) | 1993-03-05 | 1998-07-28 | Pharmacia & Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
US5730999A (en) | 1993-03-27 | 1998-03-24 | Roehm Gmbh Chemische Fabrik | Dermal therapeutic system made of a meltable poly (meth) acrylate |
US5594068A (en) | 1993-05-28 | 1997-01-14 | Eastman Chemical Company | Cellulose ester blends |
US5773490A (en) | 1993-06-24 | 1998-06-30 | Takiron Co., Ltd. | Pressure sensitive adhesive for transdermal absorption formulations |
US5853755A (en) | 1993-07-28 | 1998-12-29 | Pharmaderm Laboratories Ltd. | Biphasic multilamellar lipid vesicles |
US5354823A (en) | 1993-08-09 | 1994-10-11 | Isp Investments Inc. | Films and extrusions of cured crosslinked vinyl lactam polymer and method of preparation |
US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
US5700478A (en) | 1993-08-19 | 1997-12-23 | Cygnus, Inc. | Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity |
US5723145A (en) | 1993-09-30 | 1998-03-03 | Takiron Co., Ltd. | Transdermal absorption preparation |
US6142939A (en) | 1993-11-15 | 2000-11-07 | Spectrx, Inc. | Microporation of human skin for drug delivery and monitoring applications |
US5508367A (en) | 1993-11-29 | 1996-04-16 | Adhesives Research, Inc. | Water-soluble pressure sensitive adhesive |
US5663010A (en) | 1993-11-30 | 1997-09-02 | Olimpio Stocchiero | Device to exhaust the fumes produced inside accumulator batteries |
US5770220A (en) | 1993-12-04 | 1998-06-23 | Lts Lohmann Therapie Systeme Gmbh | Active substance-containing patch |
US5962011A (en) | 1993-12-06 | 1999-10-05 | Schering-Plough Healthcare Products, Inc. | Device for delivery of dermatological ingredients |
US5641507A (en) | 1993-12-06 | 1997-06-24 | Devillez; Richard L. | Delivery system for dermatological and cosmetic ingredients |
EP0737477A1 (en) | 1993-12-27 | 1996-10-16 | Akzo Nobel N.V. | Percutaneously absorbable preparation |
US6221383B1 (en) | 1994-01-07 | 2001-04-24 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5674561A (en) | 1994-01-28 | 1997-10-07 | Minnesota Mining And Manufacturing Company | Polymerized microemulsion pressure sensitive adhesive compositions and methods of preparing and using same |
US5527271A (en) | 1994-03-30 | 1996-06-18 | Bristol-Myers Squibb Co. | Thermoplastic hydrogel impregnated composite material |
US5851549A (en) | 1994-05-25 | 1998-12-22 | Becton Dickinson And Company | Patch, with system and apparatus for manufacture |
US5492943A (en) | 1994-06-20 | 1996-02-20 | Hollister Incorporated | Adhesive skin barrier composition for ostomy appliance |
US5726250A (en) | 1994-07-11 | 1998-03-10 | Adhesives Research, Inc. | Covalently crosslinked water-absorbent graft copolymer |
US5912271A (en) | 1994-07-12 | 1999-06-15 | Astra Ab | Pharmaceutical preparation for pain management |
US5543148A (en) | 1994-07-12 | 1996-08-06 | Combe, Incorporated | Stick delivery system for topical application of a treatment agent |
US5942543A (en) | 1994-07-15 | 1999-08-24 | Ernst; Amy A. | Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use |
US5958379A (en) | 1994-09-30 | 1999-09-28 | Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh | Pharmaceutical composition |
US5858410A (en) | 1994-11-11 | 1999-01-12 | Medac Gesellschaft Fur Klinische Spezialpraparate | Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution |
US6093328A (en) | 1994-12-08 | 2000-07-25 | Santina; Peter F. | Method for removing toxic substances in water |
WO1996019205A1 (en) | 1994-12-21 | 1996-06-27 | Theratech, Inc. | Transdermal delivery system with adhesive overlay and peel seal disc |
US5662925A (en) | 1994-12-21 | 1997-09-02 | Theratech, Inc. | Transdermal delivery system with adhesive overlay and peel seal disc |
US6696459B1 (en) | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
US5563153A (en) | 1995-02-22 | 1996-10-08 | University Of Kansas Medical Center | Sterile topical anesthetic gel |
US5990179A (en) | 1995-04-28 | 1999-11-23 | Alza Corporation | Composition and method of enhancing electrotransport agent delivery |
US6316022B1 (en) | 1995-06-07 | 2001-11-13 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
US5972377A (en) | 1995-06-07 | 1999-10-26 | Cygnus, Inc. | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
US5876746A (en) | 1995-06-07 | 1999-03-02 | Cygnus, Inc. | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
US5948416A (en) | 1995-06-29 | 1999-09-07 | The Procter & Gamble Company | Stable topical compositions |
US5780050A (en) | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
US5985311A (en) | 1995-07-22 | 1999-11-16 | Labtec Gesellschaft Fuer Techologische Forschung Und Entwicklung Mbh | Transdermal hormone patch |
US5827525A (en) | 1995-09-12 | 1998-10-27 | Bristol-Myers Squibb Company | Buccal delivery system for therapeutic agents |
US5804611A (en) | 1995-09-22 | 1998-09-08 | Kansai Paint Co., Ltd. | Composition used for hydrophilization and method for hydrophilization using said composition |
US6312670B1 (en) | 1995-09-25 | 2001-11-06 | R. Eric Montgomery | Tooth bleaching compositions |
WO1997011676A1 (en) | 1995-09-25 | 1997-04-03 | Robert Eric Montgomery | Tooth bleaching compositions |
US5827213A (en) | 1995-10-19 | 1998-10-27 | Ole R. Jensen | Heel and elbow dressing |
US5985990A (en) | 1995-12-29 | 1999-11-16 | 3M Innovative Properties Company | Use of pendant free-radically polymerizable moieties with polar polymers to prepare hydrophilic pressure sensitive adhesive compositions |
US6083421A (en) | 1996-01-19 | 2000-07-04 | Huang; Lizi | Film coating composition for whitening teeth |
US5718886A (en) | 1996-03-11 | 1998-02-17 | Laclede Professional Products, Inc. | Stabilized anhydrous tooth whitening gel |
US5645855A (en) | 1996-03-13 | 1997-07-08 | Ridge Scientific Enterprises, Inc. | Adhesive compositions including polyvinylpyrrolidone acrylic acid polymers, and polyamines |
US5846558A (en) | 1996-03-19 | 1998-12-08 | Minnesota Mining And Manufacturing Company | Ionically conductive adhesives prepared from zwitterionic materials and medical devices using such adhesives |
US6165499A (en) | 1996-03-25 | 2000-12-26 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic system with small application-area thickness and great flexibility, and production process |
US5762956A (en) | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
US5863662A (en) | 1996-05-14 | 1999-01-26 | Isp Investments Inc. | Terpolymer for ink jet recording |
US5725876A (en) | 1996-05-17 | 1998-03-10 | Noven Pharmaceuticals Inc., | Compositions and methods for using low-swell clays in nicotine containing dermal compositions |
US6146654A (en) | 1996-06-10 | 2000-11-14 | Alcare Co., Ltd. | Adhesive medical composition with sustained medicament releasbility and process for preparing same |
US5976565A (en) | 1996-06-20 | 1999-11-02 | Lavipharm Laboratories, Inc. | Device for topical treatment of acne and its method of manufacture |
US5911980A (en) | 1996-06-27 | 1999-06-15 | Macrochem Corporation | Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin |
JPH1017448A (en) | 1996-06-28 | 1998-01-20 | Lion Corp | Plaster for oral cavity |
US6007837A (en) | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture |
US6201164B1 (en) | 1996-07-11 | 2001-03-13 | Coloplast A/S | Hydrocolloid wound gel |
US5945032A (en) | 1996-09-30 | 1999-08-31 | Basf Aktiengesellschaft | Polymer/hydrogen peroxide complexes |
US5958984A (en) | 1996-10-10 | 1999-09-28 | Devillez; Richard L. | Method and composition for skin treatment |
US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
US6004578A (en) | 1996-10-24 | 1999-12-21 | Alza Corporation | Permeation enhances for transdermal drug delivery compositions, devices and methods |
EP0838225A3 (en) | 1996-10-25 | 1999-03-24 | Hiji, Yasutake | Aqueous local anesthetic solution |
US20010006677A1 (en) | 1996-10-29 | 2001-07-05 | Mcginity James W. | Effervescence polymeric film drug delivery system |
US5948430A (en) | 1996-11-11 | 1999-09-07 | Lts Lohmann Therapie-Systeme Gmbh | Water soluble film for oral administration with instant wettability |
US6709671B2 (en) | 1996-11-11 | 2004-03-23 | Lts Lohmann Therapie-Systeme Ag | Water soluble film for oral administration with instant wettability |
US6177096B1 (en) | 1996-11-11 | 2001-01-23 | Lts Lohmann Therapie-Systeme Gmbh | Water soluble film for oral administration with instant wettability |
WO1998020862A1 (en) | 1996-11-11 | 1998-05-22 | Lts Lohmann Therapie-Systeme Gmbh | Immediate wettability water soluble film or water soluble layer for oral application |
WO1998026763A1 (en) | 1996-12-16 | 1998-06-25 | Lts Lohmann Therapie-Systeme Gmbh | Active substance carrier for releasing apomorphine into the buccal cavity |
EP0848960B1 (en) | 1996-12-20 | 2002-04-24 | Röhm GmbH & Co. KG | Adhesive for dermal or transdermal therapy systems |
US6063399A (en) | 1996-12-20 | 2000-05-16 | Roehm Gmbh Chemische Fabrik | Adhesive binders for dermal or transdermal therapy systems |
US5993849A (en) | 1996-12-20 | 1999-11-30 | Roehm Gmbh Chemische Fabrik | Hydrophilic adhesive and binder for medications |
US5858332A (en) | 1997-01-10 | 1999-01-12 | Ultradent Products, Inc. | Dental bleaching compositions with high concentrations of hydrogen peroxide |
US5785527A (en) | 1997-01-10 | 1998-07-28 | Ultradent Products, Inc. | Stable light or heat activated dental bleaching compositions |
US5837713A (en) | 1997-02-26 | 1998-11-17 | Mayo Foundation For Medical Education And Research | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids |
US5879701A (en) | 1997-02-28 | 1999-03-09 | Cygnus, Inc. | Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents |
WO1998037870A1 (en) | 1997-02-28 | 1998-09-03 | Cygnus, Inc. | Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents |
US5843472A (en) | 1997-02-28 | 1998-12-01 | Cygnus, Inc. | Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use |
US6306370B1 (en) | 1997-05-30 | 2001-10-23 | Ultradent Products, Inc. | Compositions and methods for whitening and desensitizing teeth |
WO1998055044A1 (en) | 1997-06-06 | 1998-12-10 | The Procter & Gamble Company | A delivery system for a tooth whitener using a strip of material having low flexural stiffness |
US7122199B2 (en) | 1997-06-06 | 2006-10-17 | The Procter & Gamble Company | Methods for whitening teeth |
US5989569A (en) | 1997-06-06 | 1999-11-23 | The Procter & Gamble Company | Delivery system for a tooth whitener using a permanently deformable strip of material |
US5891453A (en) | 1997-06-06 | 1999-04-06 | The Procter & Gamble Company | Delivery system for a tooth whitener using a strip of material having low flexural stiffness |
US6045811A (en) | 1997-06-06 | 2000-04-04 | The Procter & Gamble Company | Delivery system for an oral care substance using a permanently deformable strip of material |
US6096328A (en) | 1997-06-06 | 2000-08-01 | The Procter & Gamble Company | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
US5879691A (en) | 1997-06-06 | 1999-03-09 | The Procter & Gamble Company | Delivery system for a tooth whitener using a strip of material having low flexural stiffness |
US5894017A (en) | 1997-06-06 | 1999-04-13 | The Procter & Gamble Company | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
US6075626A (en) | 1997-06-25 | 2000-06-13 | Denso Corporation | Hologram |
US6197331B1 (en) | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
US6068650A (en) | 1997-08-01 | 2000-05-30 | Gentronics Inc. | Method of Selectively applying needle array configurations |
WO1999007940A1 (en) | 1997-08-05 | 1999-02-18 | B-Mac, Besloten Vennootschap Met Beperkte Aansprakelijkheid | Vibrating device for processing a floor layer |
US6135126A (en) | 1997-08-07 | 2000-10-24 | Microlin, L.C. | Brush that delivers beneficial agents |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
WO1999011728A1 (en) | 1997-08-29 | 1999-03-11 | Avery Dennison Corporation | Biological fluid absorbing pressure sensitive adhesives |
US6051609A (en) | 1997-09-09 | 2000-04-18 | Tristrata Technology, Inc. | Additives enhancing the effect of therapeutic agents |
US6231885B1 (en) | 1997-09-17 | 2001-05-15 | Permatec Technologie Ag | Composition for controlled and sustained transdermal administration |
US6562363B1 (en) | 1997-09-26 | 2003-05-13 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US5945457A (en) | 1997-10-01 | 1999-08-31 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science | Process for preparing biologically compatible polymers and their use in medical devices |
WO1999017738A1 (en) | 1997-10-03 | 1999-04-15 | Lavipharm Laboratories, Inc. | A prolamine-plant polar lipid composition, its method of preparation and applications thereof |
US6212671B1 (en) | 1997-10-20 | 2001-04-03 | Mitsubishi Electric System Lsi Design Corporation | Mask pattern data producing apparatus, mask pattern data producing method and semiconductor integrated circuit device |
US5997886A (en) | 1997-11-05 | 1999-12-07 | The Procter & Gamble Company | Personal care compositions |
US6221341B1 (en) | 1997-11-19 | 2001-04-24 | Oraceutical Llc | Tooth whitening compositions |
US20010021374A1 (en) | 1997-11-19 | 2001-09-13 | Oraceutical Llc | Tooth whitening compositions |
US6072100A (en) | 1998-01-28 | 2000-06-06 | Johnson & Johnson Consumer Products, Inc. | Extrudable compositions for topical or transdermal drug delivery |
US5900249A (en) | 1998-02-09 | 1999-05-04 | Smith; David J. | Multicomponent pain relief topical medication |
US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
WO1999044678A1 (en) | 1998-03-06 | 1999-09-10 | Spectrx, Inc. | Apparatus for electroporation through microporated tissue |
WO1999047128A1 (en) | 1998-03-19 | 1999-09-23 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
EP1066823B1 (en) | 1998-03-20 | 2003-02-05 | Biocosmetics, S.L. | Tooth whitening composition |
US6419905B1 (en) | 1998-03-20 | 2002-07-16 | Biocosmetics, S.L. | Tooth whitening composition |
WO1999054422A1 (en) | 1998-04-21 | 1999-10-28 | Coloplast A/S | A pressure sensitive adhesive composition |
US5993836A (en) | 1998-04-28 | 1999-11-30 | Castillo; James G. | Topical anesthetic formulation |
WO1999055312A2 (en) | 1998-04-29 | 1999-11-04 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
US6714497B2 (en) | 1998-05-09 | 2004-03-30 | Lg Electronics Inc. | Method for forming an information recording medium having information on spare area, and method and apparatus for recording/reproducing data to/from the medium |
US20030103427A1 (en) | 1998-05-09 | 2003-06-05 | Lg Electronics Inc. | Method for forming an information recording medium having information on spare area, and method and apparatus for recording/ reproducing data to/ from the medium |
US6461636B1 (en) | 1998-05-15 | 2002-10-08 | Schwarz Pharma Ag | Transdermal therapeutic system containing pergolide |
US6451777B1 (en) | 1998-07-17 | 2002-09-17 | The University Of Texas Southwestern Medical Center | Method for regulating hair growth |
WO2000016725A3 (en) | 1998-09-18 | 2002-10-03 | Lhd Lab Hygiene Dietetique | Sterile non-adhesive compress |
US6270792B1 (en) | 1998-09-18 | 2001-08-07 | Laboratories D'hygiene Et De Dietique | Sterile nonstick compress |
US6552147B2 (en) | 1998-09-22 | 2003-04-22 | Rohm And Haas Company | Acrylic polymer compositions with crystalline side chains and processes for their preparation |
US20030055190A1 (en) | 1998-09-22 | 2003-03-20 | Hsing-Yeh Parker | Acrylic polymer compositions with crystalline side chains and processes for their preparation |
US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
CA2520986C (en) | 1998-09-25 | 2007-11-13 | Warner-Lambert Company | Physiological compatible film |
WO2000018365A2 (en) | 1998-09-25 | 2000-04-06 | Warner-Lambert Company | Fast dissolving orally consumable films |
US6708060B1 (en) | 1998-11-09 | 2004-03-16 | Transpharma Ltd. | Handheld apparatus and method for transdermal drug delivery and analyte extraction |
US6611706B2 (en) | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
US6711435B2 (en) | 1998-11-09 | 2004-03-23 | Transpharma Ltd. | Transdermal drug delivery and analyte extraction |
US6312666B1 (en) | 1998-11-12 | 2001-11-06 | 3M Innovative Properties Company | Methods of whitening teeth |
US6368576B1 (en) | 1998-11-12 | 2002-04-09 | Ultradent Products, Inc. | Methods for bleaching, opacifying and desensitizing teeth |
US6329472B1 (en) | 1998-11-18 | 2001-12-11 | Basf Aktiengesellschaft | Water-soluble or water-dispersible graft copolymers based on a polyvinyllactam, their preparation and use |
US6275728B1 (en) | 1998-12-22 | 2001-08-14 | Alza Corporation | Thin polymer film drug reservoirs |
WO2000061120A1 (en) | 1999-04-13 | 2000-10-19 | Hisamitsu Pharmaceutical Co., Inc. | Preparations for percutaneous absorption |
WO2000069421A3 (en) | 1999-05-18 | 2001-03-22 | Sanol Arznei Schwarz Gmbh | Transdermal therapeutic system (tts) containing tolterodine |
US6783769B1 (en) | 1999-05-18 | 2004-08-31 | Schwarz Pharma Ag | Transdermal therapeutic system TTS containing tolterodine |
US6962691B1 (en) | 1999-05-20 | 2005-11-08 | U & I Pharmaceuticals Ltd. | Topical spray compositions |
US6451240B1 (en) | 1999-06-09 | 2002-09-17 | The Procter & Gamble Company | Method of manufacturing an intracutaneous microneedle array |
WO2001001958A1 (en) | 1999-07-02 | 2001-01-11 | The Procter & Gamble Company | Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip |
WO2001007018A1 (en) | 1999-07-27 | 2001-02-01 | Hisamitsu Pharmaceutical Co., Inc. | Patches for external use |
WO2001026637A3 (en) | 1999-10-13 | 2001-12-13 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7384650B2 (en) | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
US20040053901A1 (en) | 1999-11-24 | 2004-03-18 | Te-Yen Chien | Transdermal hormone delivery system: compositions and methods |
US20020197284A1 (en) | 1999-12-16 | 2002-12-26 | Luo Eric C. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
US6673363B2 (en) | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
US20030104041A1 (en) | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
US6322774B1 (en) | 1999-12-20 | 2001-11-27 | Ultradent Products, Inc. | Dental bleaching compositions containing sucralose |
US6638528B1 (en) | 2000-01-20 | 2003-10-28 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
JP2001213768A (en) | 2000-02-01 | 2001-08-07 | Okayama Taiho Pharmaceutical Co Ltd | Poultice |
US6806308B2 (en) | 2000-03-06 | 2004-10-19 | Chemico Systems, Inc. | Method for protecting paint on an article, a composition useful therefor, and a method for making the composition |
US20020076487A1 (en) | 2000-03-06 | 2002-06-20 | Bohdan Zajac | Method for protecting paint on an article, a composition useful therefor, and a method for making the composition |
US20050031554A1 (en) | 2000-03-17 | 2005-02-10 | Ji-Young Kim | Patches for teeth whitening |
CA2402021C (en) | 2000-03-17 | 2005-04-12 | Lg Household & Health Care Ltd. | Patches for teeth whitening |
US20040136927A1 (en) | 2000-03-17 | 2004-07-15 | Ji-Young Kim | Apparatus and method for whitening teeth |
US20060193793A1 (en) | 2000-03-17 | 2006-08-31 | Ji-Young Kim | Apparatus and method for whitening teeth |
US20060193794A1 (en) | 2000-03-17 | 2006-08-31 | Ji-Young Kim | Patches for teeth whitening |
US6780401B2 (en) | 2000-03-17 | 2004-08-24 | Lg Household & Healthcare Ltd. | Patches for teeth whitening |
US6689344B2 (en) | 2000-03-17 | 2004-02-10 | Lg Household & Healthcare Ltd. | Patches for teeth whitening |
US6682721B2 (en) | 2000-03-17 | 2004-01-27 | Lg Household & Healthcare Ltd. | Patches for teeth whitening |
WO2001068045A1 (en) | 2000-03-17 | 2001-09-20 | Lg Household & Health Care Ltd | Patches for teeth whitening |
US20040219111A1 (en) | 2000-03-17 | 2004-11-04 | Ji-Young Kim | Method and device for teeth whitening using a dry type adhesive |
US6558654B2 (en) | 2000-04-11 | 2003-05-06 | Mclaughlin Gerald | Composition and method for whitening teeth |
US20020009420A1 (en) | 2000-04-11 | 2002-01-24 | Mclaughlin Gerald | Composition and method for whitening teeth |
US6762202B2 (en) | 2000-05-09 | 2004-07-13 | Nitromed, Inc. | Infrared thermography and methods of use |
US20010046471A1 (en) | 2000-05-09 | 2001-11-29 | Marek Przemyslaw A. | Infrared thermograpy and methods of use |
WO2001087276A1 (en) | 2000-05-16 | 2001-11-22 | Samyang Corporation | Hydrogel composition for transdermal drug delivery |
US20020004190A1 (en) | 2000-05-26 | 2002-01-10 | Adam Diasti | Method for whitening teeth |
US6517350B2 (en) | 2000-05-26 | 2003-02-11 | Dentovations Inc. | Method for whitening teeth |
US20020048602A1 (en) | 2000-06-22 | 2002-04-25 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
WO2002000182A3 (en) | 2000-06-28 | 2002-07-25 | Procter & Gamble | Structures and compositions increasing the stability of peroxide actives |
US6602912B2 (en) | 2000-06-30 | 2003-08-05 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
US6576712B2 (en) | 2000-07-07 | 2003-06-10 | A. V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
WO2002004570A3 (en) | 2000-07-07 | 2002-04-18 | Av Topchiev Inst Petrochemical | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
JP2002029949A (en) | 2000-07-19 | 2002-01-29 | Lion Corp | Composition for oral cavity |
US6667410B2 (en) | 2000-09-18 | 2003-12-23 | Board Of Regents, The University Of Texas System | Conversion of α,β-unsaturated ketones and α,β-unsaturated esters into α-hydroxy ketones and α-hydroxy esters using Mn(III) catalyst, phenylsilane and dioxygen |
US6488913B2 (en) | 2000-09-20 | 2002-12-03 | Scientific Pharmaceuticals, Inc | Two-part composition for high efficacy teeth whitening comprising a mixture of peroxides and/or percarbonates of metals |
US20020106335A1 (en) | 2000-09-20 | 2002-08-08 | Orlowski Jan A. | Two-part composition for high efficacy teeth whitening comprising a mixture of peroxides and/or percarbonates of metals |
JP2002145746A (en) | 2000-11-02 | 2002-05-22 | Haruyuki Kawahara | Tooth bleaching agent |
WO2002043657A2 (en) | 2000-11-30 | 2002-06-06 | Wm. Wrigley Jr. Company | Improved pullulan free edible film compositions and methods of making the same |
US20020131990A1 (en) | 2000-11-30 | 2002-09-19 | Barkalow David G. | Pullulan free edible film compositions and methods of making the same |
KR20020045224A (en) | 2000-12-08 | 2002-06-19 | 성재갑 | Peroxide Stabilized Patches for Teeth Whitening |
US7078359B2 (en) | 2000-12-22 | 2006-07-18 | Aspen Aerogels, Inc. | Aerogel composite with fibrous batting |
US6419906B1 (en) | 2001-03-12 | 2002-07-16 | Colgate Palmolive Company | Strip for whitening tooth surfaces |
US20030068376A1 (en) | 2001-04-20 | 2003-04-10 | Lavipharm Laboratories Inc. | Intraoral delivery of nicotine for smoking cessation |
US20120321569A1 (en) | 2001-05-01 | 2012-12-20 | Corium International, Inc. | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US20040105834A1 (en) | 2001-05-01 | 2004-06-03 | Corium International | Hydrogel compositions with an erodible backing member |
US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US8481071B2 (en) | 2001-05-01 | 2013-07-09 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
US20040258723A1 (en) | 2001-05-01 | 2004-12-23 | Parminder Singh | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US20030235549A1 (en) | 2001-05-01 | 2003-12-25 | Parminder Singh | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US20030170308A1 (en) | 2001-05-01 | 2003-09-11 | Cleary Gary W. | Hydrogel compositions |
WO2002087645A1 (en) | 2001-05-01 | 2002-11-07 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions |
US8481059B2 (en) | 2001-05-01 | 2013-07-09 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel compositions |
US20120027695A1 (en) | 2001-05-01 | 2012-02-02 | Corium International, Inc. | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US8273405B2 (en) | 2001-05-01 | 2012-09-25 | A.V. Topcheiv Institute of Petrochemical Synthesis, Russian Academy of Sciences | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US7138458B2 (en) | 2001-05-01 | 2006-11-21 | Corium International, Inc. | Method for preparing a two-phase water-absorbent bioadhesive composition |
WO2002087642A3 (en) | 2001-05-01 | 2003-01-09 | Av Topchiev Inst Petrochemical | Two-phase, water-absorbent bioadhesive composition |
US20080161492A1 (en) | 2001-05-01 | 2008-07-03 | Cleary Gary W | Two-phase, water-absorbent bioadhesive composition |
US20030152528A1 (en) | 2001-05-01 | 2003-08-14 | Parminder Singh | Hydrogel compositions for tooth whitening |
US6803420B2 (en) | 2001-05-01 | 2004-10-12 | Corium International | Two-phase, water-absorbent bioadhesive composition |
US20120237579A1 (en) | 2001-05-01 | 2012-09-20 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions with an erodible backing member |
US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
US20090258060A1 (en) | 2001-05-01 | 2009-10-15 | Cleary Gary W | Hydrogel Compositions |
WO2002089849B1 (en) | 2001-05-07 | 2003-04-03 | Corium Int | Compositions and delivery systems for administration of a local anesthetic agent |
US6591124B2 (en) | 2001-05-11 | 2003-07-08 | The Procter & Gamble Company | Portable interstitial fluid monitoring system |
US20030152615A1 (en) | 2001-06-18 | 2003-08-14 | Noven Pharmaceuticals, Inc. | Enhanced drug delivery in transdermal systems |
US6946142B2 (en) | 2001-06-23 | 2005-09-20 | Lg Household & Healthcare Ltd. | Multi-layer patches for teeth whitening |
CA2451431C (en) | 2001-06-23 | 2012-03-13 | Lg Household & Health Care Ltd. | Multiple-layered patches for teeth whitening |
KR20030000299A (en) | 2001-06-23 | 2003-01-06 | 주식회사 엘지생활건강 | Semi-transparent patches for teeth whitening |
WO2003000216A1 (en) | 2001-06-23 | 2003-01-03 | Lg Household & Health Care Ltd. | Multiple-layered patches for teeth whitening |
KR20030000528A (en) | 2001-06-26 | 2003-01-06 | 주식회사 엘지생활건강 | Patches for teeth whitening |
US6884833B2 (en) | 2001-06-29 | 2005-04-26 | 3M Innovative Properties Company | Devices, compositions, and methods incorporating adhesives whose performance is enhanced by organophilic clay constituents |
US20030100654A1 (en) | 2001-06-29 | 2003-05-29 | Theary Chheang | Devices, compositions, and methods incorporating adhesives whose performance is enhanced by organophilic clay constituents |
KR20030003969A (en) | 2001-07-04 | 2003-01-14 | 주식회사 엘지생활건강 | Manufacturing process of patches for teeth whitening |
KR20030003973A (en) | 2001-07-04 | 2003-01-14 | 주식회사 엘지생활건강 | Flexible patches for teeth whitening |
WO2003011259A1 (en) | 2001-07-30 | 2003-02-13 | Wm. Wrigley Jr. Company | Improved edible film formulations containing maltodextrin |
US20030035841A1 (en) | 2001-07-30 | 2003-02-20 | Dzija Michael R. | Edible film formulations containing maltodextrin |
US6656493B2 (en) | 2001-07-30 | 2003-12-02 | Wm. Wrigley Jr. Company | Edible film formulations containing maltodextrin |
US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
US20030101507A1 (en) | 2001-12-03 | 2003-06-05 | Cleary Stephen P. | Goggle with side arm for wearing with a helmet |
US6759030B2 (en) | 2002-03-21 | 2004-07-06 | Carl M. Kosti | Bleach stable toothpaste |
US20030180229A1 (en) | 2002-03-21 | 2003-09-25 | Kosti Carl M. | Bleach stable toothpaste |
US6750291B2 (en) | 2002-04-12 | 2004-06-15 | Pacific Corporation | Film-forming agent for drug delivery and preparation for percutaneous administration containing the same |
WO2003089046A1 (en) | 2002-04-16 | 2003-10-30 | Cyto Pulse Sciences, Inc. | Method of treating biological materials with translating electrical fields and electrode polarity reversal |
US20030225356A1 (en) | 2002-05-24 | 2003-12-04 | Kulichikhin Valery G. | Composition for cushions, wound dressings and other skin-contacting products |
US7217853B2 (en) | 2002-05-24 | 2007-05-15 | Corium International, Inc. | Composition for cushions, wound dressings and other skin-contacting products |
US7456331B2 (en) | 2002-05-24 | 2008-11-25 | Corium International, Inc. | Composition for cushions, wounds dressings and other skin-contacting products |
WO2003099344B1 (en) | 2002-05-24 | 2004-04-08 | Corium Int | Skin adhesive for cushions and wound dressings |
WO2003101357A1 (en) | 2002-05-31 | 2003-12-11 | University Of Mississippi | Transmucosal delivery of cannabinoids |
US20040005277A1 (en) | 2002-07-02 | 2004-01-08 | Willison Michael P. | Device and method for delivering an oral care agent |
US20050228113A1 (en) | 2002-08-08 | 2005-10-13 | Basf Coatings Aktiengesellschaft | Coating materials and the use thereof for the production of weldable coatings |
US20060168905A1 (en) | 2002-11-05 | 2006-08-03 | Wilfried Blanc | Light-converting material comprising a barium magenesium silicate as additive |
WO2004045569A1 (en) | 2002-11-21 | 2004-06-03 | Lg Household & Health Care Ltd. | Dry type patches safe for gum |
CA2506073C (en) | 2002-11-21 | 2009-05-26 | Lg Household & Health Care Ltd. | Dry type patches safe for gum |
US6805874B1 (en) | 2002-12-03 | 2004-10-19 | Permamed Ag | Method and skin cleansing compositions for dermatological basic treatment |
WO2004054638A3 (en) | 2002-12-13 | 2004-08-12 | Corium Int Inc | Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
US20040166147A1 (en) | 2002-12-13 | 2004-08-26 | Schering-Plough Healthcare Products, Inc. | Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
WO2004071323A3 (en) | 2003-02-05 | 2004-10-14 | Corium Int | Hydrogel compositions for tooth whitening |
US7112713B2 (en) | 2003-03-12 | 2006-09-26 | Gelsus Research And Consulting, Inc. | Dressing based on the Teorell-Meyer gradient |
WO2004093786A3 (en) | 2003-04-16 | 2006-03-23 | Corium Int | Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith |
US7323161B2 (en) | 2003-04-30 | 2008-01-29 | Icure Pharmaceutical Corp. | Patch for tooth whitening |
WO2004103201A3 (en) | 2003-05-19 | 2005-02-24 | Corium Int | Hydrogel composition demonstrating phase separation |
WO2005027768A3 (en) | 2003-09-12 | 2005-07-07 | Corium Int | Hydrogel compositions with an erodible backing member |
US20050208110A1 (en) | 2004-01-30 | 2005-09-22 | Parminder Singh | Rapidly dissolving film for delivery of an active agent |
WO2005074894A1 (en) | 2004-01-30 | 2005-08-18 | Corium International | Rapidly dissolving film for delivery of an active agent |
US20050256223A1 (en) | 2004-05-17 | 2005-11-17 | Kolb Brant U | Dental compositions containing nanozirconia fillers |
WO2006017807A3 (en) | 2004-08-05 | 2006-08-10 | Corium Int Inc | Adhesive composition |
US20060034905A1 (en) | 2004-08-05 | 2006-02-16 | Parminder Singh | Adhesive composition |
CA2579492C (en) | 2004-09-08 | 2015-06-02 | Corium International, Inc. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
WO2006029407A3 (en) | 2004-09-08 | 2006-04-20 | Corium Int Inc | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
US7744918B2 (en) | 2004-11-22 | 2010-06-29 | Hisamitsu Pharmaceutical Co., Inc. | Drug-containing patch |
US20060110434A1 (en) | 2004-11-22 | 2006-05-25 | Toshiro Yamaguchi | Drug-containing patch |
WO2006069236A3 (en) | 2004-12-21 | 2006-09-08 | Corium Int Inc | Sustained release tooth whitening formulations and systems |
US20060171906A1 (en) | 2004-12-21 | 2006-08-03 | Corium International, Inc. | Sustained release tooth whitening formulations and systems |
WO2006074173A3 (en) | 2005-01-03 | 2007-01-11 | Corium Int Inc | Water-absorbent adhesive compositions and associated methods of manufacture and use |
WO2006081497A3 (en) | 2005-01-27 | 2006-11-30 | Corium Int Inc | Hydrophilic biocompatible adhesive formulations and uses |
US20060182788A1 (en) | 2005-01-27 | 2006-08-17 | Parminder Singh | Hydrophilic biocompatible adhesive formulations and uses |
WO2006124639A1 (en) | 2005-05-11 | 2006-11-23 | Corium International, Inc. | Permeabilization of biological membranes |
WO2007119656A1 (en) | 2006-04-11 | 2007-10-25 | Nichiban Co., Ltd. | Tamsulosin-containing percutaneous absorption type preparation |
US20090155343A1 (en) | 2006-04-11 | 2009-06-18 | Nichiban Co., Ltd | Tamsulosin-Containing Transdermal Patch |
EP2005952A1 (en) | 2006-04-11 | 2008-12-24 | Nichiban Company Limited | Tamsulosin-containing percutaneous absorption type preparation |
WO2010083035A2 (en) | 2009-01-14 | 2010-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
Non-Patent Citations (74)
Title |
---|
"Aquasorb® A-500 Cellulose Gum (CMC)", Hercules Incorporated, Aqualon Division, Product Data No. 4234, 2 pgs. (2005). |
Aubin (1988), "Analysis of the Glass Transition Temperature of Miscible Polymer Blends," Macromolecules 21:2945-2949. |
Aubin et al., "Analysis of the glass transition temperature of miscible polymer blends", Macromolecules, vol. 21, pp. 2945-2949, (1988). |
Bairamov et al. (2000), "Kinetic Parameters of Poly(N-Vinyl Pyrrolidone) Spontaneous Mixing with Short-Chain Poly(Ethylene Glycol)," Polym. Mater. Sci. Eng. 82:7-8. |
Bairamov et al., "Kinetic parameters of poly(N-vinyl pyrrolidone) spontaneous mixing with short-chain poly(ethylene glycol)", Polym. Mater. Sci. Eng., vol. 82, pp. 7-8, (2000). |
Barbucci et al. "Swelling behavior of carboxymethylcellulose hydrogels in relation to cross-linking, pH, and charge density", Macromolecules, vol. 33, No. 20, pp. 7475-7480 (2000). |
Borodulina et al. "Viscoelasticity of Pressure-sensitive adhesive and bioadhesive hydrogels under compressive load", Proceed. 24th Annual Meeting Adhesion Soc., pp. 147-149, (2001). |
Borodulina et al. (2001), "Viscoelasticity of Pressure-Sensitive Adhesive and Bioadhesive Hydrogels Under Compressive Load," Proceed. 24th Annual Meeting Adhesion Soc., pp. 147-149. |
Chalykh et al. (1999), "Effects of Composition and Hydration on Adhesive Properties of Poly(N-Vinyl Pyrolidone)-Poly(Ethylene Glycol) Hydrogels," Polym. Mater. Sci. Eng 81:456-457. |
Chalykh et al., "Effects of composition and hydration on adhesive properties of poly(N-vinyl pyrrolidone)-poly(ethylene glycol) hydrogels", Polym. Mater. Sci. Eng., vol. 81, pp. 456-457, (1999). |
Chalykh et al., "Fracture mechanics of poly(N-vinyl pyrrolidone)-poly(ethylene glycol) hydrogel adhesive joints," Polym. Mater. Sci. Eng., vol. 81, pp. 427-428, (1999). |
Chalykh et al., "Pressure-sensitive adhesion in the blends of poly(N-vinyl pyrrolidone) and poly(ethylene glycol) of disparate chain lengths," J. Adhesion, vol. 78, pp. 667-694, (2002). |
Cleary et. al., A new polymer blend adhesive with combined properties to adhere to either skin or mucosa for drug delivery, podium abstract, 30th Annual Meeting and Exposition of the Controlled Release Society, Glasgow, Scotland, Jul. 19-23, 2003, Abstract #123. |
Database WPI Section Ch, Week 198451, Derwent Publications Ltd., London, GB; Class A96, AN 1984-315114 & JP 59196817 A (Sekisuki Chem Ind Co Ltd) Nov. 8, 1984 abstract. |
Database WPI Section Ch, Week 199118, Derwent Publications Ltd., London, GB; Class A96, AN 1991-128478 & JP 03066612 A (Sato Pharm Co Ltd) Mar. 22, 1991 abstract. |
Database WPI Section Ch, Week 199150, Derwent Publications Ltd., London, GB; Class A18, AN 1991-366353 & JP 03247334 A (Sumitomo Rubber Ind Ltd) Nov. 5, 1991 abstract. |
Database WPI Section Ch, Week 199627, Derwent Publications Ltd., London, GB; Class A14, AN 1996-266746 & SU 1459215 A ( A Med Cardiology Res Centre) Nov. 20, 1995 abstract. |
Emla Cream, (lidocaine 2.5% and prilocaine 2.5%), Emla Anesthetic Disc, (lidocaine 2.5% and prilocaine 2.5% cream), "Topical anesthetic for dermal analgesia", AstraZeneca Product Monograph, 46 pgs, Revised May 25, 2010. |
Feldstein et al. (1995), "Universal Hydrophilic Drug-Containing Adhesive Matrix for Systemic and Topical Transdermal Drug Delivery," Proc. 1st World Meeting APGI/APV, Budapest, 9/11. |
Feldstein et al. (1996), "Effect of Hydrophilic Matrix Hydration on Transdermal Drug Delivery Kinetics: I. The Matrix Hydration In Vivo and In Vitro," Prediction of Percutaneous Penetration 4b:61-64, Brain et al. (Eds). |
Feldstein et al. (1999), "A Structure-Property Relationship and Quantitative Approach to the Development of Universal Transdermal Drug Delivery System," NBC (Nuclear, Biological, and Chemical) Risks-Current Capabilities and Future Perspectives for Protection 25:441-458, Kluwer Academic Purlbishers, Netherlands, NATO Science Series: 1. Disarmament Technologies. |
Feldstein et al., "A new class of pressure-sensitive adhesives based on interpolyrrier and polymer-oligomer complexes", Polymer Science, vol. 51, No. 7, pp. 799-814 (2009). |
Feldstein et al., "A structure-property relationship and quantitative approach to the development of universal transdermal drug delivery system," NBC Risks, vol. 25, pp. 441-458, (1999). |
Feldstein et al., "Coherence of thermal transitions in poly(N-vinyl pyrrolidone)-poly(ethylene glycol) compatible blends: 1. Interrelations among the temperatures of melting, maximum cold crystalization rate and glass transition", Polymer, vol. 41, pp. 5327-5338, (2000). |
Feldstein et al., "Coherence of thermal transitions in poly(N-vinyl pyrrolidone)-poly(ethylene glycol) compatible blends: 2. The temperature of maximum cold crystalization rate versus glass transition", Polymer, vol. 41, pp. 5339-5348, (2000). |
Feldstein et al., "Coherence of thermal transitions in poly(N-vinyl pyrrolidone)-poly(ethylene glycol) compatible blends: 3. Impact of sorbed water upon phase behavior", Polymer, vol. 41, pp. 5349-5359, (2000). |
Feldstein et al., "Contribution of molecular mobility to debonding of pressure-sensitive adhesive hydrogels", Polym. Mater. Sci. Eng., vol. 81, pp. 467-468, (1999). |
Feldstein et al., "Correlations between activation energy for debonding and that for self-diffusion in pressure-sensitive hydrogels", Proceed. 24th Annual Meeting Adhession Soc., pp. 137-140, (2001). |
Feldstein et al., "Effect of hydrophilic matrix hydration on transdermal drug delivery kinetics: I. The matrix hydration In Vivo and In Vitro", Prediction of Percutaneous Penetration, vol. 4b, pp. 61-64, Brian, et al., (Eds.) (1996). |
Feldstein et al., "Effect of hydrophilic matrix hydration on transdermal drug delivery kinetics: II. In Vitro cytasine Delivery From Cypercuten TTS", Prediction of Percutaneous Penetration, vol. 4b, pp. 65-67, Brian, et al., (Eds.) (1996). |
Feldstein et al., "Effect of hydrophilic matrix hydration on transdermal drug delivery kinetics: III. In Vitro clonide delivery from clopercuten TTS", Prediction of Percutaneous Penetration, vol. 4b, pp. 68-70, Brian, et al., (Eds.) (1996). |
Feldstein et al., "Effect of hydrophilic matrix hydration on transdermal drug delivery kinetics: IV. In Vitro-In Vivo correlation," Prediction of Percutaneous Penetration, vol. 4b, pp. 71-73, Brian, et al., (eds.) (1996). |
Feldstein et al., "Effects of chains orientation, free volume and interaction on glass transition in poly(N-vinyl pyrrolidone)-poly(ethylene glycol) blends involving a stoichiometric hydrogen-B bonded network complex", Polym. Mater. Sci. Eng., vol. 82, pp. 365-366, (2000). |
Feldstein et al., "General approach to the molecular design of hydrophilic pressure-sensitive adhesives," Proc. 25th Ann. Mtg. and 2nd World Congress on Adhesion and Related Phenomena, Orlando, FL, vol. 1, pp. 292-294 (2002). |
Feldstein et al., "Molecular insight into rheological and diffusion determinants of pressure sensitive adhesion", Proceed. 23rd Annual Meeting Adhesion Soc., pp. 54-56, (2000). |
Feldstein et al., "Peculiarities of glass transition temperature relation to the composition of poly(N-vinyl pyrolidone) blends with short chain poly(ethylene glycol)", Polymer, vol. 42, pp. 7719-7726, (2001). |
Feldstein et al., "Quantitative relationship between molecular structure and adhesion of PVP-PEG hydrogels", Polym. Mater. Sci Eng., vol. 81, pp. 465-466, (1999). |
Feldstein et al., "Relation of glass transition temperature to the hydrogen bonding degree and energy in poly(N-vinyl pyrrolidone) blends with hydroxyl-containing plasticizers: 2. Effects of poly(ethylene glycol) chain length", Polymer, vol. 42, pp. 981-990, (2001). |
Feldstein et al., "Universal hydrophilic drug-containing adhesive matrix for systemic and topical transdermal drug delivery", Proc. 1st World Meeting APGI/APV, Budapest, 9/11, 2 pages, (1995). |
Handbook of Pharmaceutical Excipients, Arther H. Kibbe, ed., 3rd ed., pp. 401-406, (2000). |
Hawley's Condensed Chemical Dictionary, 14th Edition, Citation, "Oligomer, a polymer molecule of only a few monomer units (dimer, trimer, tetramer)", John Wiley and Sons, Inc., (2002). |
International Search Report for PCT/US/2005/028063 Mailed Apr. 28, 2006. |
International Search Report for PCT/US/2005/032525 Mailed Mar. 17, 2006. |
International Search Report for PCT/US2000/18557 mailed Oct. 17, 2000. |
International Search Report for PCT/US2001/21417 mailed Feb. 25, 2002. |
International Search Report for PCT/US2002/13680 mailed Sep. 18, 2002. |
International Search Report for PCT/US2002/14260 Mailed Sep. 17, 2002. |
International Search Report for PCT/US2002/14725 mailed Sep. 27, 2002. |
International Search Report for PCT/US2003/039717 Mailed Jun. 28, 2004. |
International Search Report for PCT/US2003/16408 Mailed Dec. 8, 2003. |
International Search Report for PCT/US2004/003443 Mailed Aug. 20, 2004. |
International Search Report for PCT/US2004/011567 Mailed Jan. 10, 2006. |
International Search Report for PCT/US2004/015448 Mailed Dec. 28, 2004. |
International Search Report for PCT/US2004/029620 Mailed Jun. 1, 2005. |
International Search Report for PCT/US2005/0002873 Mailed Apr. 27, 2005. |
International Search Report for PCT/US2005/0034439 Mailed Jul. 19, 2006. |
International Search Report for PCT/US2005/0046577 Mailed Jul. 26, 2006. |
International Search Report for PCT/US2006/0003091 Mailed Oct. 11, 2006. |
International Search Report for PCT/US2006/018500 Mailed Sep. 21, 2006. |
International Search Report for PCT/US2010/000081 Mailed Sep. 7, 2010. |
International Search Report or PCT/US/2006/000098 Mailed Nov. 3, 2006. |
Kotomin et al., "Durability and fracture of some visceolastic adhesives," Proceed. Of The 23rd Annual Meeting Of The Adhesion Soc., pp. 413-415, (Feb. 20-23, 2000). |
Kotomin et al., "Squeeze-recoil analysis of adhesive hydrogels and elastomers", Polym. Mater. Sci. Eng., vol. 81, pp. 425-426, (1999). |
MSDS (Material Safety Data Sheet), Lactic Acid, No. L0522, (2008). |
Patent Abstracts of Japan, vol. 017, No. 055 (C-I023) Feb. 3, 1993 & JP 04 266818 A (Sekisui Chem Co Ltd), Sep. 22, 1992 abstract. |
Roos et al., "Probe tack investigation of poly(vinyl pyrrolidone)-poly(ethylene glycol) blends", Proceed. 24th Annual Meeting Adhesion Soc., pp. 277-279, (2001). |
Schehlmann "Polyvinylcaprolactam: physical and cosmetic properties of a new hair fixative resin", Lecture held at the In-Cosmetics, SOFW-Journal-Sounderdruck, Dusseldorf, 6 pages (1997). |
Sintov et al., "Radiofrequency-driven skin microchanneling as a new way for electically assisted transdermal delivery of hydrophilic drugs", J. Contr.Release, vol. 89, pp. 311-320, (2003). |
Supplementary European Search Report for EP04783729.9 Mailed Jun. 5, 2009. |
U.S. Appl. No. 11/150,811, filed Jun. 10, 2005, Feldstein et al. |
U.S. Appl. No. 12/687,586, filed Jan. 11, 2009, Singh et al. |
Vartapian et al., "Molecular dynamics in poly(N-vinyl pyrrolidone)-poly(ethylene glycol) blends by pulsed-field gradient NMR method: effects of aging, hydration and PEG chain length", Macromol. Chem. Phys., vol. 202, pp. 2648-2652, (2001). |
Vartapian et al., "Self-diffusion in poly(N-vinyl pyrrolidone)-poly(ethylene glycol) systems", Colloid Polym. Sci., vol. 279, pp. 532-538, (2001). |
Whelan Polymer Technology Dictionary, Citation Butyl Rubber, Chapman Hall, 2-6 Boundry Row, London, UK, vol. 1, pp. 53 (1994). |
Also Published As
Publication number | Publication date |
---|---|
USRE44145E1 (en) | 2013-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6576712B2 (en) | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties | |
ES2587187T3 (en) | Biphasic water absorbent bioadhesive composition | |
RU2326893C2 (en) | Covalent and non-covalent linking of hydrophilic polymers and adhesive compositions with them | |
EP1951211B2 (en) | Transdermal preparations containing hydrophobic non-steroidal anti-inflammatory drugs | |
RU2411045C2 (en) | Hydrophilic biologically compatible adhesive compositions and application thereof | |
Feldstein et al. | Pressure sensitive adhesives based on interpolymer complexes | |
US8273405B2 (en) | Water-absorbent adhesive compositions and associated methods of manufacture and use | |
JP2016519058A (en) | Improved adhesive properties | |
US20050003012A1 (en) | Gel matrix consisting of polyacrylic acid and polyvinyl pyrrolidone | |
US4954343A (en) | Dermal pharmaceutical preparations | |
WO2015088368A1 (en) | Hydrophilic thermo-switchable pressure-sensitive adhesive composition | |
RU2276177C2 (en) | Preparation of hydrophilic pressure-sensitive adhesives with optimized adhesive properties | |
USRE45666E1 (en) | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties | |
JP3144895B2 (en) | Medical adhesive tape or sheet | |
AU2001273230A1 (en) | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties | |
JPH0339485B2 (en) | ||
JPH11502836A (en) | Alfuzosin delivery transdermal device | |
JPH07165563A (en) | Tape pharmaceutical preparation | |
JPS61221120A (en) | Medical material for external use | |
KR20090110255A (en) | Transdermal drug administration device | |
JP2647222B2 (en) | Transdermal formulation | |
JPH0587489B2 (en) | ||
JPH0772131B2 (en) | External patch | |
JPH01297068A (en) | Tacky adhesive agent for treatment and tacky tacky adhesive agent formulation for treatment | |
JPH064533B2 (en) | External pharmaceutical material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CAPITAL ROYALTY PARTNERS II ? PARALLEL FUND ?A? L.P., TEXAS Free format text: SECURITY INTEREST;ASSIGNOR:CORIUM INTERNATIONAL, INC.;REEL/FRAME:034535/0238 Effective date: 20141202 Owner name: CAPITAL ROYALTY PARTNERS II ? PARALLEL FUND ?B? (CAYMAN) L.P., TEXAS Free format text: SECURITY INTEREST;ASSIGNOR:CORIUM INTERNATIONAL, INC.;REEL/FRAME:034535/0238 Effective date: 20141202 Owner name: CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P., TEXAS Free format text: SECURITY INTEREST;ASSIGNOR:CORIUM INTERNATIONAL, INC.;REEL/FRAME:034535/0238 Effective date: 20141202 Owner name: CAPITAL ROYALTY PARTNERS II ? PARALLEL FUND ?A? L. Free format text: SECURITY INTEREST;ASSIGNOR:CORIUM INTERNATIONAL, INC.;REEL/FRAME:034535/0238 Effective date: 20141202 Owner name: CAPITAL ROYALTY PARTNERS II ? PARALLEL FUND ?B? (C Free format text: SECURITY INTEREST;ASSIGNOR:CORIUM INTERNATIONAL, INC.;REEL/FRAME:034535/0238 Effective date: 20141202 Owner name: CAPITAL ROYALTY PARTNERS II L.P., TEXAS Free format text: SECURITY INTEREST;ASSIGNOR:CORIUM INTERNATIONAL, INC.;REEL/FRAME:034535/0238 Effective date: 20141202 |
|
AS | Assignment |
Owner name: CORIUM INTERNATIONAL, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:CAPITAL ROYALTY PARTNERS II L.P.;CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.;CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "B" (CAYMAN) L.P.;AND OTHERS;REEL/FRAME:045513/0686 Effective date: 20180305 |
|
AS | Assignment |
Owner name: CORIUM, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:CORIUM INTERNATIONAL, INC.;REEL/FRAME:048841/0324 Effective date: 20190314 |